<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3103210655
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Sphingolin
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FINGOLIMOD HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        4450.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; V" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – V
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AA27
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Sphingolin is</p><p>The active substance of Sphingolin is fingolimod.</p><p>What Sphingolin is used for</p><p>Sphingolin is used in adults and in children and adolescents (10 years of age and above) to treat relapsing &ndash; remitting multiple sclerosis (MS), more specifically in:</p><p>-&nbsp; Patients who have failed to respond despite treatment with an MS treatment. Or</p><p>-&nbsp; Patients who have rapidly evolving severe MS.</p><p>&nbsp;</p><p>Sphingolin does not cure MS, but it helps to reduce the number of relapses and to slow down the progression of physical disabilities due to MS</p><p>What is multiple sclerosis</p><p>MS is a long-term condition that affects the central nervous system (CNS), comprised of the brain and spinal cord. In MS inflammation destroys the protective sheath (called myelin) around the nerves in the CNS and stops the nerves from working properly. This is called demyelination.</p><p>Relapsing-remitting MS is characterised by repeated attacks (relapses) of nervous system symptoms That reflect inflammation within the CNS. Symptoms vary from patient to patient but typically involve Walking difficulties, numbness, vision problems or disturbed balance. Symptoms of a relapse may disappear completely when the relapse is over, but some problems may remain.</p><p>How Sphingolin works</p><p>Sphingolin helps to protect against attacks on the CNS by the immune system by reducing the ability of some white blood cells (lymphocytes) to move freely within the body and by stopping them from reaching the brain and spinal cord. This limits nerve damage caused by MS. Sphingolin also reduces some of the immune reactions of your body.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Sphingolin</p><p>-&nbsp; if you have a <strong>lowered immune response </strong>(due to an immunodeficiency syndrome, a disease or to medicines that suppress the immune system).</p><p>-&nbsp; if you have a <strong>severe active infection or active chronic infection </strong>such as hepatitis or tuberculosis.</p><p>-&nbsp; if you have an <strong>active cancer</strong>.</p><p>-&nbsp; if you have <strong>severe liver problems</strong>.</p><p>-&nbsp;&nbsp; if, in the last 6 months, you have had heart attack, angina, stroke or warning of a stroke or certain types of heart failure.</p><p>-&nbsp;&nbsp; if you have certain types of <strong>irregular or abnormal heartbeat </strong>(arrhythmia), including patients in whom the electrocardiogram (ECG) shows prolonged QT interval before starting Sphingolin.</p><p>-&nbsp;&nbsp; <strong>if you are taking or have recently taken medicine for irregular heartbeat </strong>such as quinidine, disopyramide, amiodarone or sotalol.</p><p>-&nbsp; if you are pregnant or a woman of childbearing potential not using effective contraception.</p><p>-&nbsp;&nbsp; <strong>if you are allergic </strong>to fingolimod or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p>If this applies to you<strong>, tell your doctor without taking Sphingolin</strong>. <strong>Warnings and precautions</strong></p><p>Talk to your doctor before taking Sphingolin:</p><p>-&nbsp; if you have severe breathing problems during sleep (severe sleep apnoea).</p><p>-&nbsp; <strong>if you have been told you have an abnormal electrocardiogram.</strong></p><p>-&nbsp; <strong>if you suffer from symptoms of slow heart rate (e.g. dizziness, nausea, or palpitations)</strong>.</p><p>-&nbsp;&nbsp; <strong>if you are taking or have recently taken medicines that slow your heart rate </strong>(such as beta blockers, verapamil, diltiazem or ivabradine, digoxin, anticholinesteratic agents or pilocarpine).</p><p>-&nbsp; if you have a history of sudden loss of consciousness or fainting (syncope).</p><p>-&nbsp; <strong>if you plan to get vaccinated</strong>.</p><p>-&nbsp; <strong>if you have never had chickenpox</strong>.</p><p>-&nbsp;&nbsp; <strong>if you have or have had visual disturbances </strong>or other signs of swelling in the central vision area (macula) at the back of the eye (a condition known as macular oedema, see below), inflammation or infection of the eye (uveitis), <strong>or if you have diabetes </strong>(which can cause eye problems).</p><p>-&nbsp; if you have liver problems.</p><p>-&nbsp; if you have <strong>high blood pressure that cannot be controlled by medicines</strong>.</p><p>-&nbsp; if you have <strong>severe lung problems </strong>or smoker&rsquo;s cough.</p><p>If any of these applies to you, <strong>tell your doctor before taking Sphingolin.</strong></p><p>Slow heart rate (bradycardia) and irregular heartbeat</p><p>At the beginning of treatment or after taking the first dose of 0.5 mg when you switch from a 0.25 mg daily dose, Sphingolin causes the heart rate to slow down. As a result, you may feel dizzy or tired, or be consciously aware of your heartbeat, or your blood pressure may drop. <strong>If these effects are pronounced, tell your doctor, because you may need treatment right away. </strong>Sphingolin can also cause an irregular heartbeat, especially after the first dose. Irregular heartbeat usually returns to normal in less than one day. Slow heart rate usually returns to normal within one month.</p><p>Your doctor will ask you to stay at the surgery or clinic for at least 6 hours, with hourly pulse and blood pressure measurements, after taking the first dose of Sphingolin or after taking the first dose of</p><p>0.5 mg When you switch from a 0.25 mg daily dose, so that appropriate measures can be taken in the event of side effects that occur at the start of treatment. You should have an electrocardiogram performed prior to the first dose of Sphingolin and after the 6-hour monitoring period. Your doctor may monitor&nbsp; your electrocardiogram &nbsp;continuously during that time.&nbsp; If&nbsp; after the 6-hour period&nbsp; you</p><p>&nbsp;</p><p>have a very slow or decreasing heart rate, or if your electrocardiogram shows abnormalities, you may need to be monitored for a longer period (at least 2 more hours and possibly overnight) until these have resolved. The same May apply if you are resuming Sphingolin after a break in treatment, depending on both how long the break was and how long you had been taking Sphingolin before the break.</p><p>If you have, or if you are at risk for, an irregular or abnormal heartbeat, if your electrocardiogram is abnormal, or if you have heart disease or heart failure, Sphingolin may not be appropriate for you.</p><p>If you have a history of sudden loss of consciousness or decreased heart rate, Sphingolin may not be appropriate for you. You will be evaluated by a cardiologist (heart specialist) to advise how you should Start treatment with Sphingolin, including overnight monitoring.</p><p>If you are taking medicines that can cause your heart rate to decrease, Sphingolin may not be appropriate for you. You will need to be evaluated by a cardiologist, who will check whether you can be switched to alternative medicine that does not decrease your heart rate in order to allow treatment with Sphingolin.</p><p>If such a switch is impossible, the cardiologist will advise how you should start treatment with Sphingolin, including overnight monitoring.</p><p><u>If you have never had chickenpox</u></p><p>If you have never had chickenpox, your doctor will check your immunity against the virus that causes it (varicella zoster virus). If you are not protected against the virus, you may need a vaccination before You start treatment with Sphingolin. If this is the case, your doctor will delay the start of treatment with Sphingolin until one month after the full course of vaccination is completed <u>Infections</u></p><p>Sphingolin lowers the white blood cell count (particularly the lymphocyte count). White blood cells fight infection. While you are taking Sphingolin (and for up to 2 months after you stop taking it), you may get Infections more easily. Any infection that you already have may get worse. Infections could be serious and life-threatening. If you think you have an infection, have fever, feel like you have the flu, or have a headache accompanied by stiff neck, sensitivity to light, nausea, and/or confusion (these may be caused by a fungal infection and may be symptoms of meningitis), contact your doctor straight away, because it could be serious and life-threatening. If you believe your MS is getting worse (e.g. weakness or visual changes) or if you notice any new symptoms, talk to your doctor straight away, because these may be the symptoms of a rare brain disorder caused by</p><p>&nbsp;</p><p>infection and called progressive multifocal leukoencephalopathy (PML). PML is a serious condition that may lead to severe disability or death. Your doctor will consider performing an MRI scan to evaluate this condition and will decide whether you need to stop taking Fingolimod.</p><p>Human papilloma virus (HPV) infection, including papilloma, dysplasia, warts and HPV-related cancer, has been reported in patients treated with Sphingolin<em>. </em>Your doctor will consider whether you need to have a vaccination against HPV before starting treatment. If you are a woman, your doctor will also recommend HPV screening.</p><p><u>Macular oedema</u></p><p>Before you start Sphingolin, if you have or have had visual disturbances or other signs of swelling in the central vision area (macula) at the back of the eye, inflammation or infection of the eye (uveitis) or diabetes, your doctor may want you to undergo an eye examination.</p><p>Your doctor may want you to undergo an eye examination 3 to 4 months after starting Sphingolin Treatment.</p><p>The macula is a small area of the retina at the back of the eye which enables you to see shapes, colours, and details clearly and sharply. Sphingolin may cause swelling in the macula, a condition that is known as Macular oedema. The swelling usually happens in the first 4 months of Sphingolin treatment.</p><p>Your chance of developing macular oedema is higher if you have <strong>diabetes </strong>or have had an inflammation of the eye called uveitis. In these cases your doctor will want you to undergo regular eye examinations in order to detect macular oedema.</p><p>If you have had macular oedema, talk to your doctor before you resume treatment with Sphingolin. Macular oedema can cause some of the same vision symptoms as an MS attack (optic neuritis). Early on, there may not be any symptoms. Be sure to tell your doctor about any changes in your vision. Your doctor may want you to undergo an eye examination, especially if:</p><p>-&nbsp; The centre of your vision gets blurry or has shadows;</p><p>-&nbsp; you develop a blind spot in the centre of your vision;</p><p>-&nbsp; you have problems seeing colours or fine detail.<u> Liver function tests</u></p><p>If you have severe liver problems, you should not take Sphingolin. Sphingolin may affect your liver function. You will probably not notice any symptoms but if you notice yellowing of your skin or the</p><p>&nbsp;</p><p>whites of your eyes, abnormally dark urine or unexplained nausea and vomiting, <strong>tell your doctor straight away</strong>.</p><p>If you get any of these symptoms after starting Sphingolin, <strong>tell your doctor straight away.</strong></p><p>During the first twelve months of treatment your doctor will request blood tests to monitor your liver function. If your test results indicate a problem with your liver you may have to interrupt treatment with Sphingolin.</p><p><u>High blood pressure</u></p><p>As Sphingolin causes a slight elevation of blood pressure, your doctor may want to check your blood pressure regularly.</p><p><u>Lung problems</u></p><p>Sphingolin has a slight effect on the lung function. Patients with severe lung problems or with smoker&rsquo;s cough may have a higher chance of developing side effects.</p><p><u>Blood count</u></p><p>The desired effect of Sphingolin treatment is to reduce the amount of white blood cells in your blood. This will usually go back to normal within 2 months of stopping treatment. If you need to have any blood tests, tell the doctor that you are taking Sphingolin. Otherwise, it may not be possible for the doctor to understand the results of the test, and for certain types of blood test your doctor may need to take more blood than usual.</p><p>Before you start Sphingolin, your doctor will confirm whether you have enough white blood cells in your blood and may want to repeat a check regularly. In case you do not have enough white blood cells, you may have to interrupt treatment with Sphingolin.</p><p><u>Posterior reversible encephalopathy syndrome (PRES)</u></p><p>A condition called posterior reversible encephalopathy syndrome (PRES) has been rarely reported in MS patients treated with Sphingolin. Symptoms may include sudden onset of severe headache, confusion, seizures and vision changes. Tell your doctor straight away if you experience any of these symptoms during your treatment with Sphingolin, because it could be serious.</p><p>&nbsp;</p><p><u>Cancer</u></p><p>Skin cancers have been reported in MS patients treated with Sphingolin. Talk to your doctor straight away if you notice any skin nodules (e.g. shiny pearly nodules), patches or open sores that do not heal within weeks. Symptoms of skin cancer may include abnormal growth or changes of skin tissue</p><p>&nbsp;</p><p>(e.g. unusual moles) with a change in colour, shape or size over time. Before you start Sphingolin, a skin examination is required to check whether you have any skin nodules. Your doctor will also carry out regular skin examinations during your treatment with Sphingolin. If you develop problems with your skin, your doctor may refer you to a dermatologist, who after consultation may decide that it is important for you to be seen on a regular basis.</p><p>A type of cancer of the lymphatic system (lymphoma) has been reported in MS patients treated with Fingolimod.</p><p><u>Exposure to the sun and protection against the sun</u></p><p>Fingolimod weakens your immune system. This increases your risk of developing cancers, in particular skin cancers. You should limit your exposure to the sun and UV rays by:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wearing appropriate protective clothing.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Regularly applying sunscreen with a high degree of UV protection.<u> Unusual brain lesions associated with MS relapse</u></p><p>Rare cases of unusually large brain lesions associated with MS relapse have been reported in patients Treated with Sphingolin. In case of severe relapse, your doctor will consider performing MRI to evaluate this condition and will decide whether you need to stop taking Sphingolin.</p><p><u>Switch from other treatments to Sphingolin</u></p><p>Your doctor may switch you directly from beta interferon, glatiramer acetate or dimethyl fumarate to Sphingolin if there are no signs of abnormalities caused by your previous treatment. Your doctor may have to do a blood test in order to exclude such abnormalities. After stopping natalizumab you may have to wait for 2-3 months before starting treatment with Sphingolin. To switch from teriflunomide, your doctor may advise you to wait for a certain time or to go through an accelerated elimination procedure. If you have been treated with alemtuzumab, a thorough evaluation and discussion with your doctor is required to decide if Sphingolin is appropriate for you.</p><p><u>Women of childbearing potential</u></p><p>If used during pregnancy, Fingolimod can harm the unborn baby. Before you start treatment with Fingolimod your doctor will explain the risk to you and ask you to do a pregnancy test in order to ensure that you are not pregnant. Your doctor will give you a card which explains why you should not become pregnant while taking Fingolimod. It also explains what you should do to avoid becoming pregnant while you are taking Fingolimod. You must use effective contraception during treatment and for 2 months after stopping treatment (see section &ldquo;Pregnancy and breastfeeding&rdquo;).</p><p>&nbsp;</p><p><u>Worsening of MS after stopping Fingolimod treatment</u></p><p>Do not stop taking Sphingolin or change your dose without talking to your doctor first.</p><p>Tell your doctor straight away if you think your MS is getting worse after you have stopped treatment with Fingolimod. This could be serious (see &ldquo;If you stop taking Fingolimod&rdquo; in section 3, and also section 4, &ldquo;Possible side effects&rdquo;).</p><p>Elderly</p><p>Experience with Sphingolin in elderly patients (over 65 years) is limited. Talk to your doctor if you have any concerns.</p><p>Children and adolescents</p><p>Sphingolin is not intended for use in children below 10 years old as it has not been studied in MS patients in this age group.</p><p>The warnings and precautions listed above also apply to children and adolescents. The following Information is particularly important for children and adolescents and their caregivers:</p><p>-&nbsp;&nbsp; Before you start Sphingolin, your doctor will check your vaccination status. If you have not had certain vaccinations, it may be necessary for you to be given them before Sphingolin can be started.</p><p>-&nbsp; The first time you take Sphingolin, or when you switch from a 0.25 mg daily dose to a 0.5 mg daily dose, your doctor will monitor your heart rate and heartbeat (see &ldquo;Slow heart rate (bradycardia) and irregular heartbeat&rdquo; above).</p><p>-&nbsp; If you experience convulsions or fits before or whilst taking Sphingolin, let your doctor know.</p><p>-&nbsp;&nbsp;&nbsp; If you suffer from depression or anxiety or if you become depressed or anxious while you are Taking Sphingolin, let your doctor know. You may need to be monitored more closely.</p><p>Other medicines and Sphingolin</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Tell your doctor if you are taking any of the following medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Medicines that suppress or modulate the immune system</strong>, including <strong>other medicines used to treat MS</strong>, such as beta interferon, glatiramer acetate, natalizumab, mitoxantrone, teriflunomide, dimethyl fumarate or alemtuzumab. You must not use Sphingolin together with such medicines as this could intensify the effect on the immune system (see also &lsquo;Do not take Sphingolin&rsquo;).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Corticosteroids, </strong>due to a possible added effect on the immune system.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Vaccines</strong>. If you need to receive a vaccine, seek your doctor&rsquo;s advice first. During and for up to 2 months after treatment with Sphingolin, you should not receive certain types of vaccine (live attenuated vaccines) as they could trigger the infection that they were supposed to prevent. Other vaccines may not work as well as usual if given during this period.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Medicines that slow the heartbeat </strong>(for example beta blockers, such as atenolol). Use of Sphingolin together with such medicines could intensify the effect on heartbeat in the first days after starting Sphingolin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Medicines for irregular heartbeat</strong>, such as quinidine, disopyramide, amiodarone or sotalol. You must not use Sphingolin if you are taking such a medicine because it could intensify the effect on irregular heartbeat (see also &lsquo;Do not take Sphingolin&rsquo;).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other medicines:</p><p>&bull;&nbsp;&nbsp; protease inhibitors, anti-infectives such as ketoconazole, azole antifungals, clarithromycin or telithromycin.</p><p>&bull;&nbsp;&nbsp; carbamazepine, rifampicine, phenobarbital, phenytoin, efavirenz or St. John&rsquo;s Wort (potential risk of reduced efficacy of Sphingolin).</p><p>Pregnancy and breast-feeding</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask Your doctor for advice before taking this medicine.</p><p><u>Pregnancy</u></p><p>Do not use Fingolimod during pregnancy, if you are trying to become pregnant or if you are a woman whocould become pregnant and you are not using effective contraception. If Fingolimod is used during pregnancy, there is a risk of harm to the unborn baby. The rate of congenital malformations observed in babies exposed to Fingolimod during pregnancy is about 2 times the rate observed in the general population (in whom the rate of congenital malformations is about 2-3%). The most frequently reported malformations included cardiac, renal and musculoskeletal malformations.</p><p>Therefore, if you are a woman of childbearing potential:</p><p>-&nbsp; before you start treatment with Fingolimod your doctor will inform you about the risk to an unborn baby and ask you to do a pregnancy test in order to ensure that you are not pregnant, and,</p><p>-&nbsp;&nbsp; you must use effective contraception while taking Fingolimod and for two months after you stop taking it to avoid becoming pregnant. Talk to your doctor about reliable methods of contraception.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Your doctor will give you a card which explains why you should not become pregnant while taking</u> <u>Fingolimod.</u></p><p><strong>If you do become pregnant while taking Fingolimod, tell&nbsp; your&nbsp; doctor&nbsp; straight&nbsp; away. </strong>Your doctor will decide to stop treatment (see &ldquo;If&nbsp; you stop taking Sphingolin&rdquo; in section 3,&nbsp;&nbsp; and also section 4, &ldquo;Possible side effects&rdquo;). Specialised pre-natal monitoring will be performed. <u>Breast-feeding</u></p><p><strong>You should not breast-feed while you are taking Fingolimod. Fingolimod </strong>can pass into breast milk and there is a risk of serious side effects for the baby.</p><p>Driving and using machines</p><p>Your doctor will tell you whether your illness allows you to drive vehicles, including a bicycle, and use machines safely. Sphingolin is not expected to have an influence on your ability to drive and use machines.</p><p>However, at initiation of treatment you will have to stay at the doctor&rsquo;s surgery or clinic for 6 hours after taking the first dose of Sphingolin. Your ability to drive and use machines may be impaired during and potentially after this time period.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Treatment with Sphingolin will be overseen by a doctor who is experienced in the treatment of multiple sclerosis.</p><p>Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure. The recommended dose is:</p><p>Adults:</p><p><strong>The dose is one 0.5 mg capsule per day.</strong></p><p><strong>Children and adolescents (10 years of age and above):</strong></p><p><strong>The dose depends on body weight:</strong></p><p>&bull;&nbsp;&nbsp; Children and adolescents with body weight equal to or below 40 kg: one 0.25 mg capsule per day.</p><p>&bull;&nbsp;&nbsp; <em>Children and adolescents with body weight above 40 kg</em>: one 0.5 mg capsule per day. Children and adolescents who start on one 0.25 mg capsule per day and later reach a stable body weight above 40 kg will be instructed by their doctor to switch to one 0.5 mg capsule per day. In this case, it is recommended to repeat the first-dose observation period.</p><p>&nbsp;</p><p>Do not exceed the recommended dose. Sphingolin is for oral use.</p><p>Take Sphingolin once a day with a glass of water. Sphingolin should always be swallowed intact, Without opening them. Sphingolin can be taken with or without food. Taking Sphingolin at the same time each day will help you remember when to take your medicine.</p><p>If you have questions about how long to take Sphingolin, talk to your doctor or your pharmacist</p><p>If you take more Sphingolin than you should</p><p>If you have taken too much Sphingolin, call your doctor straight away.</p><p>If you forget to take Sphingolin</p><p>If you have been taking Sphingolin for less than 1 month and you forget to take 1 dose for a whole day, call your doctor before you take the next dose. Your doctor may decide to keep you under observation at the time you take the next dose.</p><p>If you have been taking Sphingolin for at least 1 month and have forgotten to take your treatment for more than 2 weeks, call your doctor before you take the next dose. Your doctor may decide to keep you under observation at the time you take the next dose. However, if you have forgotten to take your treatment for up to 2 weeks, you can take the next dose as planned.</p><p>Never take a double dose to make up for a forgotten dose.</p><p>If you stop taking Sphingolin</p><p>Do not stop taking Sphingolin or change your dose without talking to your doctor first.</p><p>&nbsp;</p><p>Sphingolin will stay in your body for up to 2 months after you stop taking it. Your white blood cell count (Lymphocyte count) may also remain low during this time and the side effects described in this leaflet may still occur. After stopping Sphingolin you may have to wait for 6-8 weeks before starting a new MS treatment.</p><p>If you have to restart Sphingolin more than 2 weeks after you stop taking it, the effect on heart rate normally seen when treatment is first started may re-occur and you will need to be monitored at the doctor&rsquo;s surgery or clinic for re-initiation of treatment. Do not restart Sphingolin after stopping it for more than two weeks without seeking advice from your doctor.</p><p>Your doctor will decide whether and how you need to be monitored after stopping Sphingolin. Tell your doctor straight away if you think your MS is getting worse after you have stopped treatment with Fingolimod. This could be serious.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. <u>Some side effects could be or could become serious</u></p><p><strong>Common </strong>(may affect up to 1 in 10 people):</p><p>-&nbsp; Coughing with phlegm, chest discomfort, fever (signs of lung disorders)</p><p>-&nbsp;&nbsp; Herpes virus infection (shingles or herpes zoster) with symptoms such as blisters, burning, itching or pain of the skin, typically on the upper body or the face. Other symptoms may be fever and weakness in the early stages of infection, followed by numbness, itching or red patches with severe pain</p><p>-&nbsp; Slow heartbeat (bradycardia), irregular heart rhythm</p><p>-&nbsp; A type of skin cancer called basal cell carcinoma (BCC) which often appears as a pearly nodule, although it can also take other forms</p><p>-&nbsp; Depression and anxiety are known to occur with increased frequency in the MS population and have also been reported in paediatric patients treated with Sphingolin.</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people):</p><p>-&nbsp; Pneumonia with symptoms such as fever, cough, difficulty breathing</p><p>-&nbsp;&nbsp;&nbsp; Macular oedema (swelling in the central vision area of the retina at the back of the eye) with Symptoms such as shadows or blind spot in the centre of the vision, blurred vision, problems Seeing colours or details</p><p>-&nbsp; Reduction in blood platelets which increases risk of bleeding or bruising</p><p>-&nbsp;&nbsp;&nbsp; Malignant melanoma (a type of skin cancer which usually develops from an unusual mole). Possible signs of melanoma include moles which may change size, shape, elevation or colour over time, or new moles. The moles may itch, bleed or ulcerate</p><p>-&nbsp; Convulsion, fits (more frequent in children and adolescents than in adults)</p><p><strong>Rare </strong>(may affect up to 1 in 1,000 people):</p><p>-&nbsp;&nbsp; A condition called posterior reversible encephalopathy syndrome (PRES). Symptoms may include sudden onset of severe headache, confusion, seizures and/or vision disturbances</p><p>-&nbsp; Lymphoma (a type of cancer that affects the lymph system)</p><p>-&nbsp;&nbsp; Squamous cell carcinoma: a type of skin cancer which may present as a firm red nodule, a sore with crust, or a new sore on an existing scar</p><p><strong>Very rare </strong>(may affect up to 1 in 10,000 people):</p><p>-&nbsp; Electrocardiogram anomaly (T-wave inversion)</p><p>-&nbsp; Tumour related to infection with human herpes virus 8 (Kaposi&rsquo;s sarcoma)</p><p><strong>Not known </strong>(frequency cannot be estimated from the available data):</p><p>-&nbsp;&nbsp;&nbsp; Allergic reactions, including symptoms of rash or itchy hives, swelling of lips, tongue or face, Which are more likely to occur on the day you start Sphingolin treatment</p><p>-&nbsp;&nbsp;&nbsp; Risk of a rare brain infection called progressive multifocal leukoencephalopathy (PML). The Symptoms of PML may be similar to an MS relapse. Symptoms might also arise that you might not become aware of by yourself, such as changes in mood or behaviour, memory lapses, speech and communication difficulties, which your doctor may need to investigate further to rule out PML. Therefore, if you believe your MS is getting worse or if you or those close to you notice any new or unusual symptoms, it is very important that you speak to your doctor as soon as possible</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Cryptococcal infections (a type of fungal infection), including cryptococcal meningitis with symptoms such as headache accompanied by stiff neck, sensitivity to light, nausea, and/or confusion</p><p>-&nbsp;&nbsp; Merkel cell carcinoma (a type of skin cancer). Possible signs of Merkel cell carcinoma include flesh-coloured or bluish-red, painless nodule, often on the face, head or neck. Merkel cell carcinoma can also present as a firm painless nodule or mass. Long-term exposure to the sun and a weak immune system can affect the risk of developing Merkel cell carcinoma</p><p>-&nbsp;&nbsp; After Fingolimod treatment is stopped, symptoms of MS can return and may become worse than they were before or during treatment.</p><p>-&nbsp; Autoimmune form of anaemia (decreased amount of red blood cells) where red blood cells are destroyed (autoimmune haemolytic anaemia).</p><p>If you experience any of these, <strong>tell your doctor straight away</strong>. <u>Other side effects</u></p><p><strong>Very common </strong>(may affect more than 1 in 10 people):</p><p>-&nbsp; Infection from flu virus with symptoms such as tiredness, chills, sore throat, aching in the joints Or muscles, fever</p><p>-&nbsp; Feeling of pressure or pain in the cheeks and forehead (sinusitis)</p><p>-&nbsp; Headache</p><p>-&nbsp; Diarrhoea</p><p>-&nbsp; Back pain</p><p>-&nbsp; Blood testing showing higher levels of liver enzymes</p><p>-&nbsp; Cough</p><p><strong>Common </strong>(may affect up to 1 in 10 people):</p><p>-&nbsp; Ringworm, a fungal infection of the skin (tinea versicolor)</p><p>-&nbsp; Dizziness</p><p>-&nbsp; Severe headache often accompanied by nausea, vomiting and sensitivity to light (migraine)</p><p>-&nbsp; Low level of white blood cells (lymphocytes, leucocytes)</p><p>-&nbsp; Weakness</p><p>-&nbsp; Itchy, red, burning rash (eczema)</p><p>-&nbsp; Itching</p><p>-&nbsp; Blood fat (triglycerides) level increased</p><p>-&nbsp; Hair loss</p><p>-&nbsp; Breathlessness</p><p>-&nbsp; Depression</p><p>-&nbsp; Blurred vision (see also the section on macular oedema under &ldquo;Some side effects could be or Could become serious&rdquo;)</p><p>-&nbsp; Hypertension (Sphingolin may cause a mild increase in blood pressure)</p><p>-&nbsp; Muscle pain</p><p>-&nbsp; Joint pain</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people):</p><p>-&nbsp; Low level of certain white blood cells (neutrophils)</p><p>-&nbsp; Depressed mood</p><p>-&nbsp; Nausea</p><p><strong>Rare </strong>(may affect up to 1 in 1,000 people):</p><p>-&nbsp; Cancer of the lymphatic system (lymphoma)</p><p><strong>Not known </strong>(frequency cannot be estimated from the available data):</p><p>-&nbsp; Peripheral swelling</p><p>If any of these affects you severely, <strong>tell your doctor Reporting of side effects</strong></p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.</p><p><strong><em>&nbsp;&bull; </em></strong><strong>Saudi Arabia<em>:</em></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><em>o Other GCC States:</em></strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 30&deg;C.</p><p>&bull;&nbsp; Store in the original package in order to protect from moisture.</p><p>&bull;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&bull;&nbsp; Do not use this medicine after the expiry date which is stated on the pack after EXP. The expiry date refers to the last day of the month.</p><p>&bull;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><u>Sphingolin 0.5mg</u></strong></p><p>Each Capsule contains Fingolimod hydrochloride equivalent to 0.5 mg of Fingolimod.</p><p>The other ingredients are: Powder cellulose, Titanium dioxide, Magnesium stearate.</p><p>Capsule composition: gelatin, titanium dioxide, iron oxide yellow, purified water no added preservatives</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Sphingolin looks like?



Sphingolin 0.5mg

Bright yellow cap I Opaque white body size '4' hard gelatin capsule imprinted with 'H' on cap with black ink and 'F7' on body with blue ink, filled with white to off white powder.

How supplied:

Sphingolin are supplied in Blister pack.

3 X 10's Clear PVC / PVdC-Alu Blister Pack Not all pack sizes may be marketed.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and Manufacturer</p><p>Saudi Amarox Industrial Company</p><p>Aljameah Street, Malaz quarter, Riyadh 11441 Saudi Arabia</p><p>Tel: +966 11 477 2215</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                May, 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو سفينقولن كبسول</strong></p><p dir="RTL">يحتوي سفينقولن كبسول على المادة الفعالة فينجوليمود هيدروكلوريد</p><p dir="RTL"><strong>ما هي دواعي استعمال سفينقولن كبسول</strong></p><p dir="RTL">يستخدم سفينقولن كبسول لعلاج حالة الانتكاس في التصلّب المتعدّد (MS) في البالغين والأطفال والمراهقين (10 سنوات فأكثر)، وبشكل خاص في:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرضى الذين تم علاجهم بأدوية للتصلب المتعدد ولكن كانت الاستجابة للعلاج فاشله &nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرضى الذين يواجهون تطور سريع لمرض التصلب العصبي المتعدد والشديد.</p><p dir="RTL">لا يعمل سفينقولن كبسول على علاج مرض التصلب العصبي المتعدد، لكنه يساعد على تقليل عدد الانتكاسات وإبطاء تطور الإعاقات الجسدية بسبب مرض التصلب العصبي المتعدد</p><p dir="RTL"><strong>ما هو مرض التصلب المتعدد</strong></p><p dir="RTL">مرض التصلب العصبي المتعدد هو مرض يؤدي في كثير من الأحيان إلى الإنهاك، إذ يقوم جهاز المناعة في الجسم بإتلاف الغشاء المحيط بالأعصاب في الجهاز العصبي المركزي، والذي يعمل على حمايتها والذي يسمى فقد المايلين. هذا التلف أو التآكل لغشاء المايلين يؤثر سلبا على عمل الجهاز العصبي المركزي بشكل صحيح</p><p dir="RTL">يتصف مرض التصلُّب المتعدِّد&nbsp;المتكرِّر&nbsp;بتكرار الانتكاسات لأعراض الجهاز العصبي والتي تعكس الالتهاب داخل الجهاز العصبي المركزي. تختلف الأعراض من مريض لآخر ولكن عادة ما تشتمل على صعوبات في المشي أو خدر أو مشاكل في الرؤية أو اضطراب في التوازن. قد تختفي أعراض الانتكاس تمامًا عند انتهاء الانتكاس، ولكن قد تظل هناك بعض المشكلات.</p><p dir="RTL"><strong>كيف يعمل سفينقولن كبسول</strong></p><p dir="RTL">يساعد سفينقولن كبسول على الحماية من هجمات الجهاز المناعي على الجهاز العصبي المركزي عن طريق تقليل قدرة بعض خلايا الدم البيضاء (الخلايا اللمفاوية) على التحرك بحرية داخل الجسم ومنعها من الوصول إلى الدماغ والحبل الشوكي. هذا يحد من تلف الأعصاب الناجم عن مرض التصلب العصبي المتعدد. أيضًا يقلل سفينقولن كبسول من بعض ردود الفعل المناعية لجسمك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تقم باستعمال سفينقولن كبسول:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك استجابة مناعية منخفضة (بسبب متلازمة نقص المناعة، أو مرض أو الأدوية التي تثبط الجهاز المناعي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك عدوى نشطة شديدة أو عدوى مزمنة نشطة مثل التهاب الكبد أو السل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من سرطان نشط.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل حادة في الكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تعرضت خلال الستة أشهر الماضية لنوبة قلبية أو ذبحة صدرية أو سكتة دماغية أو تحذير من سكتة دماغية أو أنواع معينة من فشل القلب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أنواع معينة من ضربات القلب غير المنتظمة أو الغير طبيعية (عدم انتظام ضربات القلب)، بما في ذلك المرضى الذين يظهر لديهم مخطط القلب الكهربائي (ECG) مع طول فترة QT قبل بدء تناول سفينقولن كبسول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أو تناولت مؤخرًا أدوية لنبض القلب غير المنتظم مثل الكينيدين أو الديسوبيراميد أو أميودارون أو السوتالول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه فينجوليمود أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</p><p dir="RTL">إذا كان هذا ينطبق عليك، أخبر طبيبك قبل تناول سفينقولن كبسول.</p><p dir="RTL"><strong>اسأل طبيبك للحصول على المشورة، إذا كنت تعتقد أنك قد تعاني من الحساسية.</strong></p><p dir="RTL"><strong>تحدث إلى طبيبك قبل تناول سفينقولن كبسول.</strong></p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong><strong> </strong></p><p dir="RTL">استشر طبيبك قبل تناول سفينقولن كبسول إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل شديدة في التنفس أثناء النوم (توقف التنفس أثناء النوم الشديد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا قيل لك أن لديك مخطط كهربية القلب غير طبيعي (رسم القلب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أعراض بطء معدل ضربات القلب (مثل الدوخة والغثيان والخفقان).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أو تناولت مؤخرًا أدوية تبطئ معدل ضربات قلبك (مثل حاصرات بيتا أو فيراباميل أو ديلتيازيم أو إيفابرادين أو الديجوكسين أو مضادات الكولينستاتيك أو بيلوكاربين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ من فقدان الوعي المفاجئ أو الإغماء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخطط للحصول على التطعيم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم تكن قد أصبت بجدري الماء من قبل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اضطرابات بصرية أو علامات تورم أخرى في منطقة الرؤية المركزية (بقعة&nbsp;العين&nbsp;البشرية) في الجزء الخلفي من العين (وهي حالة تعرف باسم وذمة البقعة الصفراء، انظر أدناه)، أو التهاب العين (التهاب القزحية)، أو إذا كنت تعاني من مرض السكري (والذي يمكن أن يسبب مشاكل في العين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل في الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك ارتفاع في ضغط الدم ولا يمكن التحكم فيه عن طريق الأدوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل شديدة في الرئة أو سعال للمدخن.</p><p dir="RTL">إذا كان أي من هذه الحالات تنطبق عليك، أخبر طبيبك قبل تناول سفينقولن كبسول.</p><p dir="RTL">بطء معدل ضربات القلب (بطء القلب) وعدم انتظام ضربات القلب</p><p dir="RTL">في بداية العلاج أو بعد تناول الجرعة الأولى البالغة 0.5 ملغم عند التبديل من جرعة يومية 0.25 ملغم، يؤدي تناول سفينقولن كبسول إلى تباطؤ معدل ضربات القلب. نتيجة لذلك، قد تشعر بالدوار أو التعب، أو تكون على دراية واعية بنبض قلبك، أو قد ينخفض ضغط الدم لديك. إذا كانت هذه الآثار واضحة، أخبر طبيبك، لأنك قد تحتاج إلى علاج على الفور. أيضا يمكن أن يسبب تناول سفينقولن كبسول عدم انتظام ضربات القلب، وخاصة بعد الجرعة الأولى. عادة ما يعود نبض القلب الغير نظامي إلى طبيعته في أقل من يوم واحد. عادة ما يعود معدل ضربات القلب البطيء إلى طبيعته خلال شهر واحد.</p><p dir="RTL">سيطلب منك طبيبك البقاء في العيادة لمدة 6 ساعات على الأقل، مع قياس النبض وضغط الدم كل ساعة، بعد تناول الجرعة الأولى من سفينقولن كبسول أو بعد تناول الجرعة الأولى والبالغة 0.5 ملغم وعند التبديل من 0.25 ملغم الجرعة اليومية، بحيث يمكن اتخاذ التدابير المناسبة في حالة حدوث آثار جانبية تزامنا مع بداية العلاج. يجب أن تقوم بعمل رسم تخطيط القلب قبل الجرعة الأولى من سفينقولن كبسول وبعد فترة المراقبة لمدة 6 ساعات. قد يراقب طبيبك رسم القلب بشكل مستمر خلال تلك الفترة. إذا كان لديك معدل ضربات القلب بطيئًا للغاية أو متناقصًا بعد فترة 6 ساعات، أو إذا أظهر تخطيط القلب الخاص بك تشوهات، فقد تحتاج إلى للمراقبة الطبية لفترة أطول (ساعتان إضافيتان على الأقل وربما ليلة وضحاها) حتى يتم حلها. قد ينطبق نفس الشيء إذا كنت تستأنف سفينقولن كبسول بعد فترة راحة من العلاج، وهذا يتوقف على كل من مدة الاستراحة وطول المدة التي تتناول خلالها سفينقولن كبسول قبل الاستراحة.</p><p dir="RTL">إذا كان لديك، أو إذا كنت في خطر من الإصابة بضربات قلب غير منتظمة أو غير طبيعية، أو إذا كان رسم القلب الكهربائي لديك غير طبيعي، أو إذا كنت تعاني من أمراض القلب أو قصور القلب، فقد لا يكون سفينقولن كبسول مناسبًا لك.</p><p dir="RTL">إذا كان لديك تاريخ من فقدان الوعي المفاجئ أو انخفاض معدل ضربات القلب، فقد لا يكون سفينقولن كبسول مناسبًا لك. سيتم تقييمك بواسطة أخصائي أمراض القلب لتقديم المشورة لكيفية البدء في العلاج باستخدام سفينقولن كبسول، بما في ذلك المراقبة الليلية.</p><p dir="RTL">إذا كنت تتناول أدوية يمكن أن تسبب انخفاض معدل ضربات القلب، فقد لا يكون سفينقولن كبسول مناسبًا لك. سوف تحتاج إلى تقييم من قبل أخصائي أمراض القلب، والذي سيتحقق مما إذا كان بإمكانك التحول إلى علاج بديل والذي لا يقلل من معدل ضربات القلب.</p><p dir="RTL">إذا كان هذا التحول مستحيلاً، فسوف ينصح أخصائي أمراض القلب كيف يجب أن تبدأ العلاج باستخدام سفينقولن كبسول، بما في ذلك المراقبة الليلية.</p><p dir="RTL"><u>إذا لم تكن قد أصبت بجدري الماء مسبقا</u></p><p dir="RTL">إذا لم تكن قد أصبت بجدري الماء من قبل، فسوف يفحص طبيبك مناعتك ضد الفيروس المسبب (فيروس الحماق). إذا لم تكن محميًا ضد الفيروس، فقد تحتاج إلى تطعيم قبل البدء في العلاج باستخدام سفينقولن كبسول. إذا كانت هذه هي الحالة، فسوف يؤخر طبيبك بدء العلاج باستخدام سفينقولن كبسول حتى شهر واحد بعد اكتمال عملية التطعيم الكاملة</p><p dir="RTL"><u>العدوى</u></p><p dir="RTL">يقلل سفينقولن كبسول من عدد خلايا الدم البيضاء (وخاصة عدد الخلايا اللمفاوية). حيث تحارب خلايا الدم البيضاء العدوى. أثناء تناولك سفينقولن كبسول (ولمدة تصل إلى شهرين بعد التوقف عن تناوله)، قد تصبح أكثر عرضه للعدوى بسهولة. أو قد تزداد العدوى الموجودة لديك بالفعل سوءا. العدوى يمكن أن تكون خطيرة وتهدد الحياة. إذا كنت تعتقد أن لديك عدوى، أو حمى، أو تشعر بأنك مصاب بالأنفلونزا، أو لديك صداع مصحوب برقبة متصلبة، وحساسية للضوء، والغثيان، و / أو الارتباك (قد يكون سببها عدوى فطرية وقد تكون الأعراض من التهاب السحايا)، اتصل بطبيبك على الفور، لأنه قد يكون خطيرًا ويهدد الحياة. إذا كنت تعتقد أن مرض التصلب العصبي المتعدد الخاص بك يزداد سوءًا (على سبيل المثال الضعف أو التغيرات البصرية) أو إذا لاحظت ظهور أي أعراض جديدة، فتحدث إلى طبيبك على الفور، لأن هذه قد تكون أعراض نادر لاضطراب في الدماغ بسبب العدوى وتسمى اعتلال الدماغ التقدمي متعدد البؤر PML وهي حالة خطيرة قد تؤدي إلى إعاقة شديدة أو وفاة.</p><p dir="RTL">تم الإبلاغ عن إصابة بفيروس الورم الحليمي البشري، بما في ذلك الورم الحليمي، خلل التنسج، الثآليل والسرطان المرتبط بفيروس الورم الحليمي البشري، في المرضى الذين عولجوا بتناول سفينقولن كبسول. سوف يفكر طبيبك فيما إذا كنت بحاجة إلى تطعيم ضد فيروس الورم الحليمي البشري قبل بدء العلاج. إذا كنت امرأة، سيوصي طبيبك أيضًا بفحصك من فيروس الورم الحليمي البشري.</p><p dir="RTL"><u>وذمة البقعة الصفراء (و</u><u>ذمة</u><u>&nbsp;بقعية)</u></p><p dir="RTL">قبل أن تبدأ في تناول سفينقولن كبسول، إذا كنت تعاني من اضطرابات بصرية أو علامات تورم أخرى في منطقة الجزء المركزي من الشبكية (البقعة) في الجزء الخلفي من العين، أو التهاب العين أو التهاب العينين أو مرض السكري، فقد يطلب طبيبك الخضوع لفحص العين.</p><p dir="RTL">قد يرغب طبيبك في الخضوع لفحص العين بعد 3 إلى 4 أشهر من بدء العلاج بتناول سفينقولن كبسول.</p><p dir="RTL">بقعة&nbsp;العين&nbsp;البشرية هي منطقة صغيرة من شبكية العين في الجزء الخلفي من العين والتي تمكنك من رؤية الأشكال والألوان والتفاصيل بوضوح وبشكل حاد. قد يسبب تناول سفينقولن كبسول تورم في البقعة، وهي حالة تعرف باسم وذمة البقعة الصفراء. يحدث التورم عادة في الأشهر الأربعة الأولى من العلاج بتناول سفينقولن كبسول.</p><p dir="RTL">تزداد فرصتك في الإصابة بالوذمة البقعية إذا كنت مصابًا بمرض السكري أو كنت تعاني من التهاب في العين يسمى التهاب القزحية. في هذه الحالات، سيطلب منك طبيبك إجراء فحوصات منتظمة للعين من أجل اكتشاف الوذمة البقعية.</p><p dir="RTL">إذا كنت قد عانيت من الوذمة البقعية، فتحدث مع طبيبك قبل استئناف العلاج مع سفينقولن كبسول.</p><p dir="RTL">يمكن أن تسبب الوذمة البقعية بعض أعراض مثل نوبة التصلب العصبي المتعدد (التهاب العصب البصري). في وقت مبكر، قد لا يكون هناك أي أعراض. تأكد من إخبار طبيبك عن أي تغييرات في رؤيتك. قد يرغب طبيبك في اخضاعك لفحص العين، خاصةً إذا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان مركز رؤيتك قد أصبح ضبابيًا أو به ظلال؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تطور البقعة العمياء في وسط رؤيتك؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك مشاكل في رؤية الألوان أو التفاصيل الدقيقة.</p><p dir="RTL"><u>اختبارات وظائف الكبد</u></p><p dir="RTL">إذا كنت تعاني من مشاكل حادة في الكبد، يجب ألا تتناول سفينقولن كبسول. قد يؤثر سفينقولن كبسول على وظائف الكبد. من المحتمل ألا تلاحظ أي أعراض، لكن إذا لاحظت اصفرار جلدك أو بياض عينيك، أو بول غامق بشكل غير طبيعي أو غثيان وقيء غير مفسرين، أخبر طبيبك على الفور.</p><p dir="RTL">إذا ظهرت لك أي من هذه الأعراض بعد بدء العلاج بتناول سفينقولن كبسول، أخبر طبيبك على الفور.</p><p dir="RTL">سيطلب طبيبك إجراء فحوصات دم لمراقبة وظائف الكبد خلال الأشهر الإثني عشر الأولى من بدء العلاج، إذا كانت نتائج الاختبار تشير إلى وجود مشكلة في الكبد، فقد تضطر إلى التوقف عن العلاج بتناول سفينقولن كبسول.</p><p dir="RTL"><u>ارتفاع ضغط الدم </u></p><p dir="RTL">بما أن سفينقولن كبسول يسبب ارتفاعًا طفيفًا في ضغط الدم، فقد يرغب طبيبك في فحص ضغط دمك بانتظام.</p><p dir="RTL"><u>مشاكل الرئة</u></p><p dir="RTL">سفينقولن كبسول له تأثير طفيف على وظيفة الرئة. المرضى الذين يعانون من مشاكل حادة في الرئة أو مع سعال المدخن قد تكون لديهم فرصة أكبر لحدوث الأعراض الجانبية.</p><p dir="RTL"><u>تعداد الدم</u></p><p dir="RTL">التأثير المطلوب لعلاج سفينقولن كبسول هو تقليل كمية خلايا الدم البيضاء في دمك. هذا عادة ما يعود إلى طبيعته خلال شهرين من توقف العلاج. إذا كنت بحاجة لإجراء أي اختبارات خاصة بالدم، أخبر الطبيب أنك تتناول سفينقولن كبسول. خلاف ذلك، قد لا يكون من الممكن للطبيب فهم نتائج الاختبار، وبالنسبة لأنواع معينة من اختبار الدم قد يحتاج طبيبك إلى أخذ كمية من الدم أكثر من المعتاد.</p><p dir="RTL">قبل أن تبدأ العلاج بتناول سفينقولن كبسول، سوف يؤكد طبيبك ما إذا كان لديك ما يكفي من خلايا الدم البيضاء في دمك وقد ترغب في تكرار الفحص بانتظام. في حال لم يكن لديك ما يكفي من خلايا الدم البيضاء، فقد تضطر إلى مقاطعة العلاج باستخدام سفينقولن كبسول.</p><p dir="RTL"><u>متلازمة اعتلال الدماغ العكسي الخلفي (</u><u>PRES</u><u>)</u></p><p dir="RTL">نادرا ما تم الإبلاغ عن حالة تسمى متلازمة اعتلال الدماغ العكسي الخلفي (PRES)</p><p dir="RTL">مرضى التصلب العصبي المتعدد الذين عولجوا باستخدام سفينقولن كبسول. قد تشمل الأعراض ظهور مفاجئ لصداع شديد، والارتباك، والنوبات وتغييرات في الرؤية. أخبر طبيبك على الفور إذا كنت تعاني من أي من هذه الأعراض أثناء علاجك بتناول سفينقولن كبسول، لأنه قد يكون خطيرًا.</p><p dir="RTL"><u>سرطان الجلد</u></p><p dir="RTL">تم الإبلاغ عن حالات سرطان الجلد في مرضى التصلب العصبي المتعدد الذين عولجوا باستخدام سفينقولن كبسول. تحدث إلى طبيبك على الفور إذا لاحظت أي عقيدات جلدية (مثل عقيدات لامعة) أو بقع أو تقرحات مفتوحة لا تلتئم خلال أسابيع. قد تشمل أعراض سرطان الجلد نموًا غير طبيعي أو تغيرات في أنسجة الجلد (مثل الشامات غير العادية) مع تغير باللون أو الشكل أو الحجم مع مرور الوقت. قبل أن تبدأ العلاج بتناول سفينقولن كبسول، يجب إجراء فحص للجلد للتحقق مما إذا كان لديك أي عقيدات جلدية. سيقوم طبيبك أيضًا بإجراء فحوصات جلدية منتظمة أثناء علاجك بتناول سفينقولن كبسول. إذا كنت تعاني من مشاكل في بشرتك، فقد يحولك طبيبك إلى طبيب أمراض جلدية، والذي قد يقرر بعد التشاور أنه من المهم أن يتم رؤيتك بشكل منتظم.</p><p dir="RTL"><u>التعرض لأشعة الشمس والحماية من أشعة الشمس</u></p><p dir="RTL">سفينقولن كبسول يضعف نظام المناعة لديك. هذا يزيد من خطر الإصابة بالسرطان، خاصة سرطان الجلد. يجب أن تحد من تعرضك لأشعة الشمس والأشعة فوق البنفسجية عن طريق:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتداء ملابس واقية مناسبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدام منتظم للمستحضرات الواقية من الشمس مع درجة عالية من الحماية من الأشعة فوق البنفسجية.</p><p dir="RTL"><u>آفات الدماغ غير عادية المرتبطة بانتكاس مرض التصلب العصبي</u></p><p dir="RTL">تم الإبلاغ عن حالات نادرة من آفات الدماغ الكبيرة غير المعتادة المرتبطة بانتكاس <u>مرض التصلب العصبي</u> في المرضى الذين يتناولون</p><p dir="RTL">سفينقولن كبسول. في حالة الانتكاس الشديد، سوف يفكر طبيبك في إجراء التصوير بالرنين المغناطيسي لتقييم هذه الحالة وسيقرر ما إذا كنت بحاجة إلى التوقف عن تناول سفينقولن كبسول.</p><p dir="RTL"><u>التبديل من العلاجات الأخرى إلى سفينقولن كبسول</u></p><p dir="RTL">قد يحولك طبيبك مباشرة من العلاج بتناول بيتا إنترفيرون أو أسيتات الغلاتيرامر أو ثنائي ميثيل فومارات إلى العلاج بتناول سفينقولن كبسول إذا لم تكن هناك علامات على وجود تحسن ملحوظ بعد استخدامك علاجك السابق. قد يتعين على طبيبك إجراء فحص الدم لاستبعاد مثل هذه الحالات الشاذة. بعد إيقاف تناول ناتاليزوماب قد تضطر إلى الانتظار لمدة 2-3 أشهر قبل بدء العلاج بتناول سفينقولن كبسول. للتبديل من تيريفلونومايد، قد ينصحك طبيبك بالانتظار لفترة معينة أو القيام بإجراء إزالة سريعة. إذا تم علاجك بـاستخدام اليمتوزوماب، فيجب إجراء تقييم شامل ومناقشة ذلك مع طبيبك لتحديد ما إذا كان سفينقولن كبسول مناسبًا لك.</p><p dir="RTL"><u>النساء ذوات القدرة على الإنجاب</u><br />إذا تم استخدام خلال فترة الحمل ، يمكن أن يؤذي فينجوليمود الجنين. قبل أن تبدأ العلاج سوف يشرح طبيبك مخاطر فينجوليمود عليك ويطلب منك<br />إجراء اختبار الحمل من أجل تأكد من أنك لست حاملاً. سيعطيك طبيبك بطاقة توضح سبب وجوب عدم الحمل أثناء تناول فينجوليمود. يشرح أيضًا<br />ما يجب عليك فعله لتجنب الحمل أثناء تناول فينجوليمود. يجب استخدام وسائل منع الحمل الفعالة أثناء العلاج ولمدة شهرين بعد التوقف عن العلاج<br />(نظر قسم &quot;الحمل والرضاعة الطبيعية) &quot; .</p><p dir="RTL"><br /><u>تفاقم التصلب المتعدد بعد التوقف عن العلاج فينجوليمود</u><br />لا تتوقف عن تناول فينجوليمود أو تغير جرعتك دون التحدث إلى طبيبك أولاً. أخبر طبيبك على الفور إذا كنت تعتقد أن مرض التصلب العصبي<br />المتعدد الخاص بك يزداد سوءًا بعد التوقف العلاج باستخدام فينجوليمود. قد يكون هذا خطيرًا (انظر &quot;إذا توقفت عن تناول فينجوليمود &quot; في القسم 3<br />، وكذلك القسم &quot; ، 4الآثار الجانبية المحتملة )</p><p dir="RTL"><strong>كبار السن</strong></p><p dir="RTL">تجربة استخدام سفينقولن كبسول من قبل المرضى المسنين (أكثر من 65 عامًا) محدودة. تحدث إلى طبيبك إذا كان لديك أي مخاوف.</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">سفينقولن كبسول ليس مخصصًا للاستخدام في الأطفال أقل من 10 سنوات لأنه لم يدرس في مرضى التصلب المتعدد في هذه الفئة العمرية.</p><p dir="RTL">تنطبق التحذيرات والاحتياطات المذكورة أعلاه أيضًا على الأطفال والمراهقين. فيما يلي معلومات مهمة بشكل خاص للأطفال والمراهقين ومقدمي الرعاية لهم:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل أن تبدأ استخدام سفينقولن كبسول، سيتحقق طبيبك من حالة التطعيم. إذا لم تكن قد تلقيت لقاحات معينة، فقد يكون من الضروري إعطاؤك هذه اللقاحات قبل بدء تناول سفينقولن كبسول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في المرة الأولى التي تتناول فيها سفينقولن كبسول، أو عندما تحول من جرعة يومية تبلغ 0.25 ملغم إلى جرعة يومية تبلغ 0.5 ملغم، فسوف يراقب طبيبك معدل ضربات القلب ونبضات القلب (انظر &quot;معدل ضربات القلب البطيء (بطء القلب) وعدم انتظام ضربات القلب&quot; أعلاه).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من تشنجات أو نوبات قبل أو أثناء تناول سفينقولن كبسول، أخبر طبيبك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الاكتئاب أو القلق أثناء تناولك سفينقولن كبسول، أخبر طبيبك. قد تحتاج إلى أن يتم ملاحظتك عن كثب من قبل الطبيب.</p><p dir="RTL"><strong>تناول أدوية أخرى مع سفينقولن كبسول </strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت أي أدوية أخرى مؤخرًا. بما في ذلك الأدوية التي تم الحصول عليها دون وصفة طبية.</p><p dir="RTL">من المهم أن تخبر طبيبك أو الصيدلي إذا كنت تتناول أيًا مما الأدوية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تثبط أو تعدل الجهاز المناعي، بما في ذلك الأدوية الأخرى المستخدمة لعلاج مرض التصلب العصبي المتعدد، مثل بيتا انترفيرون، أسيتات الغلاتيرامر، ناتاليزوماب، ميتوكسانترون، تيريفلونوميد، ثنائي ميثيل فومارات أو أليمتوزوماب. يجب ألا تستخدم سفينقولن كبسول مع هذه الأدوية مثل هذا قد يؤدي إلى تكثيف التأثير على الجهاز المناعي (انظر أيضًا &quot;لا تتناول سفينقولن كبسول&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الستيرويدات القشرية، بسبب التأثير الإضافي المحتمل على الجهاز المناعي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اللقاحات. إذا كنت بحاجة إلى تلقي تطعيم، فاطلب النصيحة من طبيبك أولاً. أثناء العلاج ولمدة تصل إلى شهرين بعد باستخدام سفينقولن كبسول، يجب ألا تتلقى أنواعًا معينة من التطعيمات (اللقاحات الموهنة الحية) لأنها يمكن أن تؤدي إلى الإصابة التي كان من المفترض أن تمنعها. قد لا تعمل اللقاحات الأخرى بشكل طبيعي إذا تم تناولها خلال هذه الفترة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تبطئ نبضات القلب (على سبيل المثال حاصرات بيتا، مثل الأتينولول). استخدام سفينقولن كبسول مع هذه الأدوية يمكن أن يكثف التأثير على دقات القلب في الأيام الأولى بعد بدء العلاج بتناول سفينقولن كبسول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لنبض القلب غير المنتظم، مثل الكينيدين أو الديسوبيراميد أو أميودارون أو السوتالول. يجب ألا تستخدم سفينقولن كبسول إذا كنت تتناول مثل هذه الأدوية لأنه قد يزيد من التأثير على نبضات القلب الغير منتظمة (انظر أيضًا &quot;لا تتناول سفينقولن كبسول&quot;).</p><p dir="RTL">أدوية أخرى:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات الأنزيم البروتيني، مضادات العدوى مثل الكيتوكونازول، مضادات الفطريات الآزول، الكلاريثروميسين أو التليثروميسين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كاربامازيبين، ريفامبيسين، فينوباربيتال، فينيتوين، إفافيرينز أو نبتة سانت جون (خطر محتمل من تقليل فعالية سفينقولن كبسول).</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنت حاملاً أو ترضعين طفلك، أو تعتقدين أنك حامل أو تخططين لإنجاب طفل، فاطلب نصيحة الطبيب قبل تناول هذا الدواء.</p><p dir="RTL"><u>الحمل:</u></p><p dir="RTL">لا تستخدم فينجوليمود أثناء الحمل، إذا كنت تحاولين الحمل أو إذا كنت حاملا او امرأة يمكنها أ تصبح حاملاً ولا تستخدم وسائل منع الحمل<br />الفعالة. إذا كان فينجوليمود مستخدم أثناء الحمل، فهناك خطر من حدوث ضرر على الجنين . معدل التشوهات الخلقي التي لوحظت في الأطفال<br />المعرضين لفينجوليمود أثناء الحمل تبلغ حوالي ضعف المعدل الملحوظ في شكل عام (حيث يبلغ معدل التشوهات الخلقية حوالي .)٪ 3-2وشملت<br />أكثر التشوهات التي تم الإبلاغ نها تكرا ًرا أمراض القلب والكلص تشوهات العضلات الهيكلية.<br />لذلك، إذا كنت امرأة لديها إمكانات الإنجاب:<br />- قبل أ تبدأ العلاج بفينجوليمود، سيخبرك طبيبك خطورته على الجنين ويطلب منك إجراء اختبار الحمل للتأكد من أنك لست حاملاً، و<br />- يجب استخدام وسائل منع الحمل الفعالة أثناء تناول فينجوليمود ولمدة شهرين بعد التوقف من أخذه لتجنب الحمل. تحدثي مع طبيبك حول الطرق<br />الموثوقة لمنع الحمل<br /><u>سيعطيك طبيبك بطاقة توضح ضرورة عدم حملك أثناء تناولك فينجوليمود</u><u>.</u><br />إذا أصبحت حاملاً أثناء تناول فينجوليمود، أخبر طبيبك على الفور. طبيبك سيقرر التوقف عن العلاج (انظر &quot;إذا توقفت تناول فينجوليمود &quot; في<br />القسم ،3وأيضًا القسم &quot; 4الآثار الجانبية المحتملة)&quot;. سيتم إجراء مراقبة متخصصة قبل الولادة</p><p dir="RTL">الرضاعة الطبيعية<br />يجب عليك عدم الرضاعة الطبيعية أثناء تناول فينجوليمود. يمكن أن ينتقل فينجوليمود إلى حليب الثدي وسيكون هناك خطر من آثار جانبية خطيرة<br />للطفل</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">قبل أن تبدأ العلاج بتناول سفينقولن كبسول، قد يطلب منك طبيبك إجراء اختبار حمل للتأكد من أنك لست حاملاً. يجب تجنب الحمل أثناء تناول سفينقولن كبسول أو في الشهرين التاليين بعد التوقف عن تناوله لأن هناك خطر حدوث ضرر للطفل. تحدث مع طبيبك حول الطرق الموثوقة لتحديد النسل والتي يجب عليك استخدامها أثناء العلاج ولمدة شهرين بعد توقف العلاج.</p><p dir="RTL">إذا أصبحت حاملاً أثناء العلاج بتناول سفينقولن كبسول، فيجب التوقف عن تناول الدواء وأخبر طبيبك على الفور. ستقرر أنت وطبيبك ما هو الأفضل لك ولطفلك.</p><p dir="RTL">يجب ألا ترضعين طفلك أثناء تناولك سفينقولن كبسول. يمكن أن ينتقل سفينقولن كبسول إلى حليب الأم وهناك خطر حدوث آثار جانبية خطيرة على الطفل.</p><p dir="RTL">&nbsp; اسأل طبيبك أو الصيدلي للحصول على المشورة قبل تناول أي دواء.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">سيخبرك طبيبك ما إذا كان مرضك يسمح لك بقيادة المركبات، بما في ذلك الدراجة، واستخدام الآلات بأمان. ليس من المتوقع أن يكون لتناول سفينقولن كبسول تأثير على قدرتك على القيادة واستخدام الآلات.</p><p dir="RTL">ومع ذلك، عند بدء العلاج، يجب عليك البقاء في العيادة لمدة 6 ساعات</p><p dir="RTL">بعد تناول الجرعة الأولى من سفينقولن كبسول. قد تنخفض قدرتك على القيادة واستخدام الآلات خلال هذه الفترة الزمنية وربما بعدها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيتم الإشراف على العلاج باستخدام سفينقولن كبسول من قبل طبيب من ذوي الخبرة في علاج مرض التصلب المتعدد.</p><p dir="RTL">دائما تناول هذا الدواء تماما كما أخبر طبيبك. استشر طبيبك إذا كنت غير متأكد. الجرعة الموصي بها هي:</p><p dir="RTL"><strong>الكبار:</strong></p><p dir="RTL">جرعة واحدة كبسولة 0.5 ملغم يوميا.</p><p dir="RTL"><strong>الأطفال والمراهقون (10 سنوات فأكثر):</strong></p><p dir="RTL">تعتمد الجرعة على وزن الجسم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأطفال والمراهقون الذين يقل وزنهم عن 40 كجم أو أقل: كبسولة 0.25 ملغم لكل يوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأطفال والمراهقون الذين تزيد أوزانهم عن 40 كجم: كبسولة واحدة 0.5 ملغم يوميًا. الأطفال والمراهقون الذين يبدأون بتناول كبسولة واحدة 0.25 ملغم يوميًا ويصلون بعد ذلك إلى وزن جسم ثابت أكثر من 40 كيلوجرام، سيتم توجيههم من قبل الطبيب للتبديل إلى كبسولة واحدة 0.5 ملغم يوميًا. في هذه الحالة، يوصى بتكرار فترة مراقبة الجرعة الأولى.</p><p dir="RTL">لا تتجاوز الجرعة الموصي بها.</p><p dir="RTL"><strong>سفينقولن كبسول للاستخدام عن طريق الفم.</strong></p><p dir="RTL">تناول سفينقولن كبسول مرة واحدة في اليوم مع كوب من الماء. يجب دائمًا ابتلاع سفينقولن كبسول، بدون فتحه. يمكن أن تتناول سفينقولن كبسول مع أو بدون طعام. تناول سفينقولن كبسول في نفس الوقت كل يوم سوف يساعدك على تذكر متى تتناول الدواء.</p><p dir="RTL">إذا كانت لديك أسئلة حول المدة التي تستغرقها في تناول سفينقولن كبسول، فتحدث إلى طبيبك أو الصيدلي</p><p dir="RTL"><strong>الجرعة الزائدة من سفينقولن كبسول</strong></p><p dir="RTL">إذا تناولت جرعة زائدة من سفينقولن كبسول، فاتصل بطبيبك على الفور.</p><p dir="RTL"><strong>نسيان تناول أقراص من سفينقولن كبسول</strong></p><p dir="RTL">إذا كنت تتناول سفينقولن كبسول لمدة تقل عن شهر واحد ونسيت أن تتناول جرعة واحدة ليوم كامل، فاتصل بطبيبك قبل أن تتناول الجرعة التالية. قد يقرر طبيبك إبقائك تحت الملاحظة في الوقت الذي تتناول فيه الجرعة التالية.</p><p dir="RTL">إذا كنت تتناول سفينقولن كبسول لمدة شهر على الأقل ونسيت تناول علاجك لأكثر من أسبوعين، فاتصل بطبيبك قبل أن تتناول الجرعة التالية. قد يقرر طبيبك إبقائك تحت الملاحظة في الوقت الذي تتناول فيه الجرعة التالية. ومع ذلك، إذا نسيت تناولك العلاج لمدة تصل إلى أسبوعين، فيمكنك تناول الجرعة التالية كما هو مخطط لها.</p><p dir="RTL">لا تأخذ جرعة مضاعفة لتعويض جرعة منسية.</p><p dir="RTL"><strong>التوقف عن تناول سفينقولن كبسول</strong></p><p dir="RTL">لا تتوقف عن تناول سفينقولن كبسول أو تغير جرعتك دون التحدث إلى طبيبك أولاً.</p><p dir="RTL">يتبقى سفينقولن كبسول في جسمك لمدة تصل إلى شهرين بعد التوقف عن التناول. قد يظل عدد خلايا الدم البيضاء (عدد الخلايا اللمفاوية) منخفضًا أيضًا خلال هذا الوقت وقد لا تزال تحدث الآثار الجانبية الموضحة في هذه النشرة. بعد إيقاف تناول سفينقولن كبسول، قد تضطر إلى الانتظار لمدة 6-8 أسابيع قبل بدء علاج جديد لمرض التصلب العصبي المتعدد.</p><p dir="RTL">إذا اضطررت إلى إعادة العلاج بتناول سفينقولن كبسول بعد أكثر من أسبوعين من التوقف عن تناوله، فقد يحدث تأثير على معدل ضربات القلب الذي يظهر عادة عند بدء العلاج لأول مرة، وسوف تحتاج إلى مراقبته في عيادة الطبيب لإعادة البدء بالعلاج. لا تقم بإعادة العلاج بتناول سفينقولن كبسول بعد إيقافه لأكثر من أسبوعين دون طلب المشورة من طبيبك.</p><p dir="RTL">سيقرر طبيبك ما إذا كنت تحتاج مراقبة طبية بعد إيقاف تناول سفينقولن كبسول وكيف ذلك.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثاراً جانبية، على الرغم من عدم حدوثها للجميع.</p><p dir="RTL">بعض الآثار الجانبية يمكن أن تكون أو تصبح خطيرة</p><p dir="RTL"><strong>شائع</strong> (قد يؤثر على شخص واحد من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال مع البلغم، والشعور بعدم الراحة في الصدر، والحمى (علامات اضطرابات الرئة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى فيروس الهربس (القوباء المنطقية أو القوباء النطاقية) بأعراض مثل ظهور بثور أو حروق أو حكة أو ألم في الجلد، عادة على الجزء العلوي من الجسم أو الوجه. قد تكون الأعراض الأخرى هي الحمى وضعف في المراحل المبكرة من الإصابة، تليها خدر أو حكة أو بقع حمراء مع ألم شديد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبضات بطيئة (بطء القلب)، عدم انتظام ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع من سرطان الجلد يسمى سرطان الخلايا القاعدية (BCC) والذي غالبًا ما يظهر كعقدة لؤلؤية، على الرغم من أنه يمكن أن يأخذ أشكالًا أخرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من المعروف أن الاكتئاب والقلق يحدثان مع زيادة المعدلات في مرض التصلب العصبي المتعدد، كما تم الإبلاغ عنهما في مرضى الأطفال الذين عولجوا بتناول سفينقولن كبسول.</p><p dir="RTL"><strong>غير شائع</strong> (قد يؤثر على شخص واحد من بين كل 100 شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاب الرئوي مع أعراض مثل الحمى والسعال وصعوبة التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوذمة البقعية (تورم في منطقة الرؤية المركزية للشبكية في الجزء الخلفي من العين) مع أعراض مثل الظلال أو البقعة العمياء في مركز الرؤية، أو عدم وضوح الرؤية، أو مشاكل رؤية الألوان أو التفاصيل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الصفائح الدموية مما يزيد من خطر النزيف أو الكدمات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الجلد الخبيث (نوع من سرطان الجلد الذي عادة ما يتطور من الشامات الغير عادية) تشمل العلامات المحتملة للورم الميلاني الشامات التي قد تغير الحجم أو الشكل أو الارتفاع أو اللون مع مرور الوقت أو الشامات الجديدة. الشامات قد تكون مثيرة للحكة، النزف أو التقرح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنج، والنوبات (بمعدلات أكثر في الأطفال والمراهقين أكثر من البالغين)</p><p dir="RTL"><strong>نادر</strong> (قد يؤثر على شخص واحد من كل 1000 شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة تسمى متلازمة اعتلال الدماغ العكسي الخلفي (PRES). قد تشمل الأعراض ظهور مفاجئ لصداع شديد، والارتباك، ونوبات و / أو اضطرابات في الرؤية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الغدد الليمفاوية (نوع من السرطان يصيب الجهاز اللمفاوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الخلايا الحرشفية: نوع من سرطان الجلد الذي قد يظهر كعقدة حمراء قوية، أو التهاب في القشرة، أو التهاب جديد في ندبة موجودة.</p><p dir="RTL"><strong>نادر جدًا</strong> (قد يؤثر على ما يصل إلى شخص واحد من كل 10000 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في رسم القلب (انعكاس الموجة T)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ورم مرتبط بالعدوى بفيروس الهربس البشري 8 (ساركوما كابوسي)</p><p dir="RTL">معدل الآثار الجانبية التالية <strong>غير معروف</strong> (لا يمكن تقدير معدلاتها من البيانات المتاحة):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية، بما في ذلك أعراض الطفح الجلدي أو حكة، تورم الشفاه، اللسان أو الوجه، والتي من المرجح أن تحدث في يوم بدء العلاج بتناول سفينقولن كبسول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خطر حدوث عدوى نادرة في الدماغ تسمى اعتلال الدماغ التقدمي متعدد البؤر (PML). قد تكون أعراض PML مشابهة لإنتكاسة MS. قد تظهر الأعراض أيضًا مع أنك قد لا تدركها بنفسك، مثل التغييرات في الحالة المزاجية أو السلوك، أو فقدان الذاكرة، أو صعوبات النطق والتواصل، والتي قد يحتاج إليها طبيبك لمزيد من البحث لاستبعاد PML. لذلك، إذا كنت تعتقد أن مرض التصلب العصبي المتعدد الخاص بك يزداد سوءًا أو إذا لاحظت أنك أو المقربون منك أي أعراض جديدة أو غير عادية، فمن المهم للغاية أن تتحدث إلى طبيبك في أقرب وقت ممكن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى بالمكورات العقدية (نوع من أنواع العدوى الفطرية)، بما في ذلك التهاب السحايا بالمكورات العقدية مع أعراض مثل الصداع المصحوب برقبة متصلبة، وحساسية للضوء، والغثيان، و / أو الارتباك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان خلايا ميركل (نوع من سرطان الجلد). تشمل العلامات المحتملة لسرطان خلايا ميركل لونًا مثل لون اللحم أو أحمر مزرق، عقيدًات غير مؤلمة، غالبًا على الوجه أو الرأس أو الرقبة. يمكن لسرطان خلايا ميركل أن يظهر كعقدة أو كتلة غير مؤلمة. التعرض لفترة طويلة لأشعة الشمس وضعف جهاز المناعة يمكن أن يؤثر على خطر الإصابة بسرطان خلايا ميركل</p><p dir="RTL">إذا واجهت أيًا من هذه الأمور، أخبر طبيبك على الفور.</p><p dir="RTL"><u>آثار جانبية أخرى</u></p><p dir="RTL"><strong>شائع جدًا</strong> (قد يؤثر على أكثر من شخص من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى من فيروس الانفلونزا مع أعراض مثل التعب، قشعريرة، التهاب الحلق، آلام في المفاصل أو العضلات والحمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضغط أو الألم في الخدين والجبهة (التهاب الجيوب الأنفية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع الراس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الظهر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فحص الدم يظهر مستويات أعلى من إنزيمات الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;سعال</p><p dir="RTL">شائع (قد يؤثر على شخص واحد من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعفة، التهاب فطري في الجلد (سعفة متعددة الألوان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع شديد غالبًا ما يكون مصحوبًا بالغثيان والقيء والحساسية للضوء (الصداع النصفي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى خلايا الدم البيضاء (الخلايا اللمفاوية، الكريات البيض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة، طفح جلدي والتهابات (الأكزيما)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تهيج بالجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى الدهون في الدم (الدهون الثلاثية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط شعر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كآبة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية (انظر أيضًا القسم الخاص بالوذمة البقعية تحت عنوان &quot;بعض الآثار الجانبية قد تكون أو قد تصبح خطيرة&quot;)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم (قد يسبب سفينقولن كبسول زيادة طفيفة في ضغط الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم عضلي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الم المفاصل</p><p dir="RTL"><strong>غير شائع</strong> (قد يؤثر على شخص واحد من بين كل 100 شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى بعض خلايا الدم البيضاء (نقص العدلات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مكتئب المزاج</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان</p><p dir="RTL"><strong>نادر</strong> (قد يؤثر على شخص واحد من كل 1000 شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الجهاز اللمفاوي (سرطان الغدد الليمفاوية)</p><p dir="RTL"><strong>غير معروف</strong> (لا يمكن تقدير معدلاتها من البيانات المتاحة):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم محيطي</p><p dir="RTL">إذا كان أي منها يؤثر عليك بشدة، أخبر طبيبك</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية: </strong></p><p dir="RTL">إذا زادت حدة أي من هذه الأعراض الجانبية، أو لاحظت ظهور أعراض جانبية غير ما تم ذكره في هذه النشرة، يرجى إبلاغ الطبيب المعالج أو الصيدلي. وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة (انظر التفاصيل أدناه). بالإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير مزيد من المعلومات حول أمان هذا الدواء.</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p dir="RTL"><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span dir=LTR></span><span
  dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span></span><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; فاكس 7662-205-1-966+</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الاتصال على المركز الوطني للتيقظ والسلامة الدوائية +966-11-2038222 ، تحويلة: 2317-2356-2353-2354-2334-2340</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الهاتف المجاني: 8002490000</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني : npc .drug@sfda .gov .sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: www .sfda .gov .sa/npc</p></td></tr></tbody></table><!--[if mso & !supportInlineShapes & supportFields]><span
  dir=LTR><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:453.6pt;
   height:90.7pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span></span><![endif]--><p>&nbsp;</p><p dir="RTL"><strong>دول مجلس التعاون الخليجي الأخرى:</strong></p><p dir="RTL">&nbsp; &nbsp;يرجى الاتصال بالسلطة الصحية المختصة .</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ عند درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في عبوته الأصلية لحمايته من الرطوبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول أيدي الأطفال أو على مرأى منهم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم سفينقولن كبسول بعد انتهاء تاريخ الصلاحية المذكور على العبوة الخارجية. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي أن يتم التخلص من الأدوية في مياه الصرف الصحي أوعن طريق النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. هذه التدابير تساعد في الحفاظ على البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما تحتويه سفينقولن كبسول </strong></p><p dir="RTL"><strong><u>سفينقولن كبسول 0.5 ملغم</u></strong></p><p dir="RTL">كل كبسولة تحتوي على فينجوليمود هيدروكلوريد يعادل 0.5 ملغم من فينجوليمود.</p><p dir="RTL"><strong>الصواغات الأخرى هي</strong>: مسحوق السليلوز، ثاني أكسيد التيتانيوم، ستيرات الماغنيسيوم.</p><p dir="RTL"><strong>مكونات الكبسولة:</strong> الجيلاتين، وثاني أكسيد التيتانيوم، وأكسيد الحديد الأصفر، والمياه النقية لا توجد مواد حافظة مضافة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو شكل سفينقولن كبسول ومحتويات العلبة؟</strong></p><p dir="RTL"><strong><u>سفينقولن كبسول 0.5 ملغم</u></strong></p><p dir="RTL">كبسولات جيلاتينية صلبة معتمة مقاس 4 ذات اللون الأصفر الزاهي ومطبوع على غطاء الكبسولة بالحبر الأسود حرف &#39;H&#39; و &#39;F7&#39; على الجسم بالحبر الأزرق، الكبسولات تحتوي على مسحوق أبيض إلى أبيض قاتم.</p><p dir="RTL"><strong>توافر سفينقولن كبسول:</strong></p><p dir="RTL">يتوافر سفينقولن كبسول في عبوات حاوية.</p><p dir="RTL">تحتوي عبوة سفينقولن كبسول 30 كبسولة عبارة عن ثلاثة شرائط مصنوعة من Alu. PVC/PVDC بكل منها 10 كبسولات</p><p dir="RTL">قد لا تتوافر كافة العبوات في السوق</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب حق التسويق:</strong></p><p dir="RTL"><strong>شركة أماروكس السعودية للصناعة</strong></p><p dir="RTL">شارع الجامعة &ndash; الملز &ndash; الرياض 11441</p><p dir="RTL">المملكة العربية السعودية.</p><p dir="RTL">تليفون: + 966 114772215</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر/2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sphingolin 0.5mg 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sphingolin 0.5mg 
  Each Capsule contains Fingolimod hydrochloride equivalent to 0.5 mg of Fingolimod. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sphingolin 0.5mg 
Bright yellow cap I Opaque white body size '4' hard gelatin capsule imprinted with 'H' on cap with black ink and 'F7' on body with blue ink, filled with white to off white powder. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fingolimod Tablets is indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult patients and paediatric patients aged 10 years and older:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4.4 and 5.1).</p><p>or</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain</p><p>MRI or a significant increase in T2 lesion load as compared to a previous recent MRI</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The treatment should be initiated and supervised by a physician experienced in multiple sclerosis.</p><p>Posology&nbsp;</p><p>In adults, the recommended dose of Fingolimod Tablets is one 0.5 mg capsule taken orally once daily.</p><p>In paediatric patients (10 years of age and above), the recommended dose is dependent on body weight:</p><p>-&nbsp;&nbsp; Pediatric patients with body weight &le;40 kg: one 0.25 mg capsule taken orally once daily.</p><p>-&nbsp;&nbsp; Paediatric patients with body weight &gt;40 kg: one 0.5 mg capsule taken orally once daily.</p><p>Paediatric patients who start on 0.25 mg capsules and subsequently reach a stable body weight above 40 kg should be switched to 0.5 mg capsules.</p><p>When switching from a 0.25 mg to a 0.5 mg daily dose, it is recommended to repeat the same first dose monitoring as for treatment initiation.</p><p>Fingolimod Tablets can be taken with or without food.</p><p>The capsules should always be swallowed intact, without opening them.</p><p>The same first dose monitoring as for treatment initiation is recommended when treatment is interrupted for:</p><p>-&nbsp;&nbsp; 1 day or more during the first 2 weeks of treatment.</p><p>-&nbsp;&nbsp; more than 7 days during weeks 3 and 4 of treatment.</p><p>-&nbsp;&nbsp; more than 2 weeks after one month of treatment.</p><p>If the treatment interruption is of shorter duration than the above, the treatment should be continued with the next dose as planned (see section 4.4).</p><p>Special populations&nbsp;</p><p>Elderly population &nbsp;</p><p>Fingolimod Tablets should be used with caution in patients aged 65 years and over due to insufficient data on safety and efficacy (see section 5.2).</p><p>Renal impairment &nbsp;</p><p>Fingolimod Tablets was not studied in patients with renal impairment in the multiple sclerosis pivotal studies. Based on clinical pharmacology studies, no dose adjustments are needed in patients with mild to severe renal impairment.</p><p>Hepatic impairment &nbsp;</p><p>Fingolimod Tablets must not be used in patients with severe hepatic impairment (Child-Pugh class C) (see section 4.3). Although no dose adjustments are needed in patients with mild or moderate hepatic impairment, caution should be exercised when initiating treatment in these patients (see sections 4.4 and 5.2).</p><p>Paediatric population &nbsp;</p><p>The safety and efficacy of Fingolimod Tablets in children aged below 10 years have not yet been established. No data are available.</p><p>There are very limited data available in children between 10&ndash;12 years old (see sections 4.4, 4.8 and 5.1).</p><p>Method of administration&nbsp;</p><p>This medicinal product is for oral use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Immunodeficiency syndrome. 
-	Patients with increased risk for opportunistic infections, including immunocompromised patients (including those currently receiving immunosuppressive therapies or those immunocompromised by prior therapies). 
-	Severe active infections, active chronic infections (hepatitis, tuberculosis). 
-	Active malignancies. 
-	Severe liver impairment (Child-Pugh class C). 
-	Patients who in the previous 6 months had myocardial infarction (MI), unstable angina pectoris, stroke/transient ischaemic attack (TIA), decompensated heart failure (requiring inpatient treatment), or New York Heart Association (NYHA) class III/IV heart failure (see section 4.4). - Patients with severe cardiac arrhythmias requiring anti-arrhythmic treatment with class Ia or class III anti-arrhythmic medicinal products (see section 4.4). 
-	Patients with second-degree Mobitz type II atrioventricular (AV) block or third-degree AV block, or sick-sinus syndrome, if they do not wear a pacemaker (see section 4.4). 
-	Patients with a baseline QTc interval ≥ 500 msec (see section 4.4). 
-	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bradyarrhythmia&nbsp;</p><p>Initiation of Fingolimod Tablets treatment results in a transient decrease in heart rate and may also be associated with atrioventricular conduction delays, including the occurrence of isolated reports of transient, spontaneously resolving complete AV block (see sections 4.8 and 5.1).</p><p>After the first dose, the decline in heart rate starts within one hour, and is maximal within 6 hours. This post-dose effect persists over the following days, although usually to a milder extent, and usually abates over the next weeks. With continued administration, the average heart rate returns towards baseline within one month. However individual patients may not return to baseline heart rate by the end of the first month. Conduction abnormalities were typically transient and asymptomatic. They usually did not require treatment and resolved within the first 24 hours on treatment. If necessary, the decrease in heart rate induced by fingolimod can be reversed by parenteral doses of atropine or isoprenaline.</p><p>All patients should have an ECG and blood pressure measurement performed prior to and 6</p><p>hours after the first dose of Fingolimod Tablets. All patients should be monitored for a period of 6 hours for signs and symptoms of bradycardia with hourly heart rate and blood pressure measurement. Continuous (real time) ECG monitoring during this 6 hour period is recommended.</p><p>The same precautions as for the first dose are recommended when patients are switched from the</p><p>0.25 mg to the 0.5 mg daily dose.</p><p>Should post-dose bradyarrhythmia-related symptoms occur, appropriate clinical management should be initiated and monitoring should be continued until the symptoms have resolved. Should a patient require pharmacological intervention during the first-dose monitoring, overnight monitoring in a medical facility should be instituted and the first-dose monitoring should be repeated after the second dose of Fingolimod Tablets.</p><p>If the heart rate at 6 hours is the lowest since the first dose was administered (suggesting that the maximum pharmacodynamic effect on the heart may not yet be manifest), monitoring should be extended by at least 2 hours and until heart rate increases again. Additionally, if after 6 hours, the heart rate is &lt;45 bpm in adults, &lt;55 bpm in paediatric patients aged 12 years and above, or &lt;60 bpm in paediatric patients aged 10 to below 12 years, or the ECG shows new onset second degree or higher grade AV block or a QTc interval &ge;500 msec, extended monitoring (at least overnight monitoring), should be performed, and until the findings have resolved. The occurrence at any time of third degree AV block should also lead to extended monitoring (at least overnight monitoring).</p><p>The effects on heart rate and atrioventricular conduction may recur on re-introduction of Fingolimod Tablets treatment depending on duration of the interruption and time since start of Fingolimod Tablets treatment. The same first dose monitoring as for treatment initiation is recommended when treatment is interrupted for:</p><p>-&nbsp;&nbsp; 1 day or more during the first 2 weeks of treatment.</p><p>-&nbsp;&nbsp; more than 7 days during weeks 3 and 4 of treatment.</p><p>-&nbsp;&nbsp; more than 2 weeks after one month of treatment.</p><p>If the treatment interruption is of shorter duration than the above, the treatment should be continued with the next dose as planned.</p><p>Very rare cases of T-wave inversion have been reported in adult patients treated with fingolimod. In case of T-wave inversion, the prescriber should ensure that there are no associated myocardial ischaemia signs or symptoms. If myocardial ischaemia is suspected, it is recommended to seek advice from a cardiologist.</p><p>Due to the risk of serious rhythm disturbances or significant bradycardia, Fingolimod Tablets should not be used in patients with sino-atrial heart block, a history of symptomatic bradycardia, recurrent syncope or cardiac arrest, or in patients with significant QT prolongation (QTc&gt;470 msec [adult female], QTc &gt;460 msec [paediatric female] or &gt;450 msec [adult and paediatric male]), uncontrolled hypertension or severe sleep apnoea (see also section 4.3). In such patients, treatment with Fingolimod Tablets should be considered only if the anticipated benefits outweigh the potential risks, and advice from a cardiologist sought prior to initiation of treatment in order to determine the most appropriate monitoring. At least overnight extended monitoring is recommended for treatment initiation (see also section 4.5).</p><p>Fingolimod Tablets has not been studied in patients with arrhythmias requiring treatment with class Ia (e.g. quinidine, disopyramide) or class III (e.g. amiodarone, sotalol) antiarrhythmic medicinal products. Class Ia and class III antiarrhythmic medicinal products have been associated with cases of torsades de pointes in patients with bradycardia (see section 4.3).</p><p>Experience with Fingolimod Tablets is limited in patients receiving concurrent therapy with beta blockers, heart-rate-lowering calcium channel blockers (such as verapamil or diltiazem), or other substances which may decrease heart rate (e.g. ivabradine, digoxin, anticholinesteratic agents or pilocarpine). Since the initiation of Fingolimod Tablets treatment is also associated with slowing of the heart rate (see also section 4.8, Bradyarrhythmia), concomitant use of these substances during Fingolimod Tablets initiation may be associated with severe bradycardia and heart block. Because of the potential additive effect on heart rate treatment with Fingolimod Tablets should not be initiated in patients who are concurrently treated with these substances (see also section 4.5). In such patients, treatment with Fingolimod Tablets should be considered only if the anticipated benefits outweigh the potential risks. If treatment with Fingolimod Tablets is considered, advice from a cardiologist should be sought regarding the switch to non heart-rate lowering medicinal products prior to initiation of treatment. If the heart-rate-lowering medication cannot be stopped, cardiologist&#39;s advice should be sought to determine appropriate first dose monitoring, at least overnight extended monitoring is recommended (see also section 4.5).</p><p>QT interval&nbsp;</p><p>In a thorough QT interval study of doses of 1.25 or 2.5 mg fingolimod at steady-state, when a negative chronotropic effect of fingolimod was still present, fingolimod treatment resulted in a prolongation of QTcI, with the upper limit of the 90% CI &le;13.0 ms. There is no dose- or exposure-response relationship of fingolimod and QTcI prolongation. There is no consistent signal of increased incidence of QTcI outliers, either absolute or change from baseline, associated with fingolimod treatment.</p><p>The clinical relevance of this finding is unknown. In the multiple sclerosis studies, clinically relevant effects on prolongation of the QTc-interval have not been observed but patients at risk for QT prolongation were not included in clinical studies.</p><p>Medicinal products that may prolong QTc interval are best avoided in patients with relevant risk factors, for example, hypokalaemia or congenital QT prolongation.</p><p>Immunosuppressive effects&nbsp;</p><p>Fingolimod has an immunosuppressive effect that predisposes patients to an infection risk, including opportunistic infections that can be fatal, and increases the risk of developing lymphomas and other malignancies, particularly those of the skin. Physicians should carefully monitor patients, especially those with concurrent conditions or known factors, such as previous immunosuppressive therapy. If this risk is suspected, discontinuation of treatment should be considered by the physician on a case-by-case basis (see also section 4.4 &ldquo;Infections&rdquo; and &ldquo;Cutaneous neoplasms&rdquo; and section 4.8 &ldquo;Lymphomas&rdquo;).</p><p>Infections&nbsp;</p><p>A core pharmacodynamic effect of Fingolimod Tablets is a dose-dependent reduction of the peripheral lymphocyte count to 20-30% of baseline values. This is due to the reversible sequestration of lymphocytes in lymphoid tissues (see section 5.1).</p><p>Before initiating treatment with Fingolimod Tablets, a recent complete blood count (CBC) (i.e. within 6 months or after discontinuation of prior therapy) should be available. Assessments of CBC are also recommended periodically during treatment, at month 3 and at least yearly thereafter, and in case of signs of infection. Absolute lymphocyte count &lt;0.2x10<sup>9</sup>/l, if confirmed, should lead to treatment interruption until recovery, because in clinical studies, fingolimod treatment was interrupted in patients with absolute lymphocyte count &lt;0.2x10<sup>9</sup>/l.</p><p>Initiation of treatment with Fingolimod Tablets should be delayed in patients with severe active infection until resolution.</p><p>Patients need to be assessed for their immunity to varicella (chickenpox) prior to Fingolimod Tablets treatment. It is recommended that patients without a health care professional confirmed history of chickenpox or documentation of a full course of vaccination with varicella vaccine undergo antibody testing to varicella zoster virus (VZV) before initiating Fingolimod Tablets therapy. A full course of vaccination for antibody-negative patients with varicella vaccine is recommended prior to commencing treatment with Fingolimod Tablets (see section 4.8). Initiation of treatment with Fingolimod Tablets should be postponed for 1 month to allow full effect of vaccination to occur.</p><p>The immune system effects of Fingolimod Tablets may increase the risk of infections, including opportunistic infections (see section 4.8). Effective diagnostic and therapeutic strategies should be employed in patients with symptoms of infection while on therapy. When evaluating a patient with a suspected infection that could be serious, referral to a physician experienced in treating infections should be considered. During treatment, patients receiving Fingolimod Tablets should be instructed to report promptly symptoms of infection to their physician.</p><p>Suspension of Fingolimod Tablets should be considered if a patient develops a serious infection and consideration of benefit-risk should be undertaken prior to re-initiation of therapy.</p><p>Cases of cryptococcal meningitis (a fungal infection), sometimes fatal, have been reported in the post-marketing setting after approximately 2-3 years of treatment, although an exact relationship with the duration of treatment is unknown (see section 4.8). Patients with symptoms and signs consistent with cryptococcal meningitis (e.g. headache accompanied by mental changes such as confusion, hallucinations, and/or personality changes) should undergo prompt diagnostic evaluation. If cryptococcal meningitis is diagnosed, fingolimod should be suspended and appropriate treatment should be initiated. A multidisciplinary consultation (i.e. infectious disease specialist) should be undertaken if re-initiation of fingolimod is warranted.</p><p>Progressive multifocal leukoencephalopathy (PML) has been reported under fingolimod treatment since marketing authorisation (see section 4.8). PML is an opportunistic infection caused by John Cunningham virus (JCV), which may be fatal or result in severe disability. Cases of PML have occurred after approximately 2-3 years of monotherapy treatment without previous exposure to natalizumab, although an exact relationship with the duration of treatment is unknown. Additional PML cases have occurred in patients who had been treated previously with natalizumab, which has a known association with PML. PML can only occur in the presence of a JCV infection. If JCV testing is undertaken, it should be considered that the influence of lymphopenia on the accuracy of anti-JCV antibody testing has not been studied in fingolimodtreated patients. It should also be noted that a negative anti-JCV antibody test does not preclude the possibility of subsequent JCV infection. Before initiating treatment with fingolimod, a baseline MRI should be available (usually within 3 months) as a reference. During routine MRI (in accordance with national and local recommendations), physicians should pay attention to PML suggestive lesions. MRI may be considered as part of increased vigilance in patients considered at increased risk of PML. If PML is suspected, MRI should be performed immediately for diagnostic purposes and treatment with fingolimod should be suspended until PML has been excluded.</p><p>Human papilloma virus (HPV) infection, including papilloma, dysplasia, warts and HPV-related cancer, has been reported under treatment with fingolimod in the post-marketing setting. Due to the immunosuppressive properties of fingolimod, vaccination against HPV should be considered prior to treatment initiation with fingolimod taking into account vaccination recommendations. Cancer screening, including Pap test, is recommended as per standard of care.</p><p>Elimination of fingolimod following discontinuation of therapy may take up to two months and vigilance for infection should therefore be continued throughout this period. Patients should be instructed to report symptoms of infection up to 2 months after discontinuation of fingolimod.</p><p>Macular oedema&nbsp;</p><p>Macular oedema with or without visual symptoms has been reported in 0.5% of patients treated with fingolimod 0.5 mg, occurring predominantly in the first 3-4 months of therapy (see section 4.8). An ophthalmological evaluation is therefore recommended at 3-4 months after treatment initiation. If patients report visual disturbances at any time while on therapy, evaluation of the fundus, including the macula, should be carried out.</p><p>Patients with history of uveitis and patients with diabetes mellitus are at increased risk of macular oedema (see section 4.8). Fingolimod Tablets has not been studied in multiple sclerosis patients with concomitant diabetes mellitus. It is recommended that multiple sclerosis patients with diabetes mellitus or a history of uveitis undergo an ophthalmological evaluation prior to initiating therapy and have follow-up evaluations while receiving therapy.</p><p>Continuation of Fingolimod Tablets in patients with macular oedema has not been evaluated. It is recommended that Fingolimod Tablets be discontinued if a patient develops macular oedema. A decision on whether or not Fingolimod Tablets therapy should be re-initiated after resolution of macular oedema needs to take into account the potential benefits and risks for the individual patient.</p><p>Liver function&nbsp;</p><p>Increased hepatic enzymes, in particular alanine aminotransaminase (ALT) but also gamma glutamyltransferase (GGT) and aspartate transaminase (AST) have been reported in multiple sclerosis patients treated with Fingolimod Tablets. In clinical trials, elevations 3-fold the upper limit of normal (ULN) or greater in ALT occurred in 8.0% of adult patients treated with fingolimod 0.5 mg compared to 1.9% of placebo patients. Elevations 5-fold the ULN occurred in 1.8% of patients on fingolimod and 0.9% of patients on placebo. In clinical trials, fingolimod was discontinued if the elevation exceeded 5 times the ULN. Recurrence of liver transaminase elevations occurred with rechallenge in some patients, supporting a relationship to fingolimod. In clinical studies, transaminase elevations occurred at any time during treatment although the majority occurred within the first 12 months. Serum transaminase levels returned to normal within approximately 2 months after discontinuation of fingolimod.</p><p>Fingolimod Tablets has not been studied in patients with severe pre-existing hepatic injury (Child-Pugh class C) and should not be used in these patients (see section 4.3).</p><p>Due to the immunosuppressive properties of fingolimod, initiation of treatment should be delayed in patients with active viral hepatitis until resolution.</p><p>Recent (i.e. within last 6 months) transaminase and bilirubin levels should be available before initiation of treatment with Fingolimod Tablets. In the absence of clinical symptoms, liver transaminases should be monitored at months 1, 3, 6, 9 and 12 on therapy and periodically thereafter. If liver transaminases rise above 5 times the ULN, more frequent monitoring should be instituted, including serum bilirubin and alkaline phosphatase (ALP) measurement. With repeated confirmation of liver transaminases above 5 times the ULN, treatment with Fingolimod Tablets should be interrupted and only re-commenced once liver transaminase values have normalised.</p><p>Patients who develop symptoms suggestive of hepatic dysfunction, such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or dark urine, should have liver enzymes checked and Fingolimod Tablets should be discontinued if significant liver injury is confirmed (for example liver transaminase levels greater than 5-fold the ULN and/or serum bilirubin elevations). Resumption of therapy will be dependent on whether or not another cause of liver injury is determined and on the benefits to patient of resuming therapy versus the risks of recurrence of liver dysfunction.</p><p>Although there are no data to establish that patients with pre-existing liver disease are at increased risk of developing elevated liver function tests when taking Fingolimod Tablets, caution in the use of Fingolimod Tablets should be exercised in patients with a history of significant liver disease.</p><p>Interference with serological testing&nbsp;</p><p>Since fingolimod reduces blood lymphocyte counts via re-distribution in secondary lymphoid organs, peripheral blood lymphocyte counts cannot be utilised to evaluate the lymphocyte subset status of a patient treated with Fingolimod Tablets. Laboratory tests involving the use of circulating mononuclear cells require larger blood volumes due to reduction in the number of circulating lymphocytes.</p><p>Blood pressure effects&nbsp;</p><p>Patients with hypertension uncontrolled by medication were excluded from participation in premarketing clinical trials and special care is indicated if patients with uncontrolled hypertension are treated with Fingolimod Tablets.</p><p>In MS clinical trials, patients treated with fingolimod 0.5 mg had an average increase of approximately 3 mmHg in systolic pressure, and approximately 1 mmHg in diastolic pressure, first detected approximately 1 month after treatment initiation, and persisting with continued treatment. In the two-year placebo-controlled study, hypertension was reported as an adverse event in 6.5% of patients on fingolimod 0.5 mg and in 3.3% of patients on placebo. Therefore, blood pressure should be regularly monitored during treatment with Fingolimod Tablets.</p><p>Respiratory effects&nbsp;</p><p>Minor dose-dependent reductions in values for forced expiratory volume (FEV<sub>1</sub>) and diffusion capacity for carbon monoxide (DLCO) were observed with Fingolimod Tablets treatment starting at month 1 and remaining stable thereafter. Fingolimod Tablets should be used with caution in patients with severe respiratory disease, pulmonary fibrosis and chronic obstructive pulmonary disease (see also section 4.8).</p><p>Posterior reversible encephalopathy syndrome&nbsp;</p><p>Rare cases of posterior reversible encephalopathy syndrome (PRES) have been reported at the 0.5 mg dose in clinical trials and in the post-marketing setting (see section 4.8). Symptoms reported included sudden onset of severe headache, nausea, vomiting, altered mental status, visual disturbances and seizure. Symptoms of PRES are usually reversible but may evolve into ischemic stroke or cerebral haemorrhage. Delay in diagnosis and treatment may lead to permanent neurological sequelae. If PRES is suspected, Fingolimod Tablets should be discontinued.</p><p>Prior treatment with immunosuppressive or immunomodulatory therapies&nbsp;</p><p>There have been no studies performed to evaluate the efficacy and safety of Fingolimod Tablets when switching patients from teriflunomide, dimethyl fumarate or alemtuzumab treatment to Fingolimod Tablets. When switching patients from another disease modifying therapy to Fingolimod Tablets, the half-life and mode of action of the other therapy must be considered in order to avoid an additive immune effect whilst at the same time minimising the risk of disease reactivation. A CBC is recommended prior to initiating Fingolimod Tablets to ensure that immune effects of the previous therapy (i.e. cytopenia) have resolved.</p><p>Fingolimod Tablets can generally be started immediately after discontinuation of interferon or glatiramer acetate.</p><p>For dimethyl fumarate, the washout period should be sufficient for CBC to recover before treatment with Fingolimod Tablets is started.</p><p>Due to the long half-life of natalizumab, elimination usually takes up to 2-3 months following discontinuation. Teriflunomide is also eliminated slowly from the plasma. Without an accelerated elimination procedure, clearance of teriflunomide from plasma can take from several months up to 2 years. An accelerated elimination procedure as defined in the teriflunomide summary of product characteristics is recommended or alternatively washout period should not be shorter than 3.5 months. Caution regarding potential concomitant immune effects is required when switching patients from natalizumab or teriflunomide to Fingolimod Tablets.</p><p>Alemtuzumab has profound and prolonged immunosuppressive effects. As the actual duration of these effects is unknown, initiating treatment with Fingolimod Tablets after alemtuzumab is not recommended unless the benefits of such treatment clearly outweigh the risks for the individual patient.</p><p>A decision to use prolonged concomitant treatment with corticosteroids should be taken after careful consideration.</p><p>Co-administration with potent CYP450 inducers&nbsp;</p><p>The combination of fingolimod with potent CYP450 inducers should be used with caution.</p><p>Concomitant administration with St John&#39;s wort is not recommended (see section 4.5).</p><p>Cutaneous neoplasms&nbsp;</p><p>Basal cell carcinoma (BCC) and other cutaneous neoplasms, including malignant melanoma, squamous cell carcinoma, Kaposi&#39;s sarcoma and Merkel cell carcinoma, have been reported in patients receiving Fingolimod Tablets (see section 4.8). Vigilance for skin lesions is warranted and a medical evaluation of the skin is recommended at initiation, and then every 6 to 12 months taking into consideration clinical judgement. The patient should be referred to a dermatologist in case suspicious lesions are detected.</p><p>Since there is a potential risk of malignant skin growths, patients treated with fingolimod should be cautioned against exposure to sunlight without protection. These patients should not receive concomitant phototherapy with UV-B-radiation or PUVA-photo chemotherapy.</p><p>Tumefactive lesions&nbsp;</p><p>Rare cases of tumefactive lesions associated with MS relapse were reported in the postmarketing setting. In case of severe relapses, MRI should be performed to exclude tumefactive lesions. Discontinuation of Fingolimod Tablets should be considered by the physician on a caseby-case basis taking into account individual benefits and risks.</p><p>Return of disease activity (rebound)&nbsp;</p><p>In the post-marketing setting, severe exacerbation of disease has been observed rarely in some patients stopping fingolimod. The possibility of recurrence of exceptionally high disease activity should be considered (see &ldquo;Stopping therapy&rdquo; below).</p><p>Stopping therapy&nbsp;</p><p>If a decision is made to stop treatment with Fingolimod Tablets a 6 week interval without therapy is needed, based on half-life, to clear fingolimod from the circulation (see section 5.2). Lymphocyte counts progressively return to normal range within 1-2 months of stopping therapy in most patients (see section 5.1) although full recovery can take significantly longer in some patients. Starting other therapies during this interval will result in concomitant exposure to fingolimod. Use of immunosuppressants soon after the discontinuation of Fingolimod Tablets may lead to an additive effect on the immune system and caution is therefore indicated.</p><p>Caution is also indicated when stopping fingolimod therapy due to the risk of a rebound (see</p><p>&ldquo;Return of disease activity (rebound)&rdquo; above). If discontinuation of Fingolimod Tablets is deemed necessary, patients should be monitored during this time for relevant signs of a possible rebound.</p><p>Paediatric population&nbsp;</p><p>The safety profile in paediatric patients is similar to that in adults and the warnings and precautions for adults therefore also apply to paediatric patients.</p><p>In particular, the following should be noted when prescribing Fingolimod Tablets to paediatric patients:</p><p>-&nbsp;&nbsp; Precautions should be followed at the time of the first dose (see &ldquo;Bradyarrhythmia&rdquo; above). The same precautions as for the first dose are recommended when patients are switched from the 0.25 mg to the 0.5 mg daily dose.</p><p>-&nbsp;&nbsp; In the controlled paediatric trial D2311, cases of seizures, anxiety, depressed mood and depression have been reported with a higher incidence in patients treated with fingolimod compared to patients treated with interferon beta-1a. Caution is required in this subgroup population (see &ldquo;Paediatric population&rdquo; in section 4.8).</p><p>-&nbsp;&nbsp; Mild isolated bilirubin increases have been noted in paediatric patients on Fingolimod Tablets.</p><p>-&nbsp;&nbsp; It is recommended that paediatric patients complete all immunisations in accordance with current immunisation guidelines before starting Fingolimod Tablets therapy (see &ldquo;Infections&rdquo; above).</p><p>-&nbsp;&nbsp; There are very limited data available in children between 10&ndash;12 years old, less than 40 kg or at Tanner stage &lt;2 (see sections 4.8 and 5.1). Caution is required in these subgroups due to very limited knowledge available from the clinical study.</p><p>-&nbsp;&nbsp; Long-term safety data in the paediatric population are not available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Anti-neoplastic, immunomodulatory or immunosuppressive therapies&nbsp;</p><p>Anti-neoplastic, immunomodulatory or immunosuppressive therapies should not be coadministered due to the risk of additive immune system effects (see sections 4.3 and 4.4).</p><p>Caution should also be exercised when switching patients from long-acting therapies with immune effects such as natalizumab, teriflunomide or mitoxantrone (see section 4.4). In multiple sclerosis clinical studies the concomitant treatment of relapses with a short course of corticosteroids was not associated with an increased rate of infection.</p><p>Vaccination&nbsp;</p><p>During and for up to two months after treatment with Fingolimod Tablets vaccination may be less effective. The use of live attenuated vaccines may carry a risk of infections and should therefore be avoided (see sections 4.4 and 4.8).</p><p>Bradycardia-inducing substances&nbsp;</p><p>Fingolimod has been studied in combination with atenolol and diltiazem. When fingolimod was used with atenolol in an interaction study in healthy volunteers, there was an additional 15% reduction of heart rate at fingolimod treatment initiation, an effect not seen with diltiazem. Treatment with Fingolimod Tablets should not be initiated in patients receiving beta blockers, or other substances which may decrease heart rate, such as class Ia and III antiarrhythmics, calcium channel blockers (such as verapamil or diltiazem), ivabradine, digoxin, anticholinesteratic agents or pilocarpine because of the potential additive effects on heart rate (see sections 4.4 and 4.8). If treatment with Fingolimod Tablets is considered in such patients, advice from a cardiologist should be sought regarding the switch to non heart-rate lowering medicinal products or appropriate monitoring for treatment initiation, at least overnight monitoring is recommended, if the heart-rate-lowering medication cannot be stopped.</p><p>Pharmacokinetic interactions of other substances on fingolimod&nbsp;</p><p>Fingolimod is metabolised mainly by CYP4F2. Other enzymes like CYP3A4 may also contribute to its metabolism, notably in the case of strong induction of CYP3A4. Potent inhibitors of transporter proteins are not expected to influence fingolimod disposition. Coadministration of fingolimod with ketoconazole resulted in a 1.7-fold increase in fingolimod and fingolimod phosphate exposure (AUC) by inhibition of CYP4F2. Caution should be exercised with substances that may inhibit CYP3A4 (protease inhibitors, azole antifungals, some macrolides such as clarithromycin or telithromycin).</p><p>Co-administration of carbamazepine 600 mg twice daily at steady-state and a single dose of fingolimod 2 mg reduced the AUC of fingolimod and its metabolite by approximately 40%. Other strong CYP3A4 enzyme inducers, for example rifampicin, phenobarbital, phenytoin, efavirenz and St. John&#39;s Wort, may reduce the AUC of fingolimod and its metabolite at least to this extent. As this could potentially impair the efficacy, their co-administration should be used with caution. Concomitant administration with St. John&#39;s Wort is however not recommended (see section 4.4).</p><p>Pharmacokinetic interactions of fingolimod on other substances&nbsp;</p><p>Fingolimod is unlikely to interact with substances mainly cleared by the CYP450 enzymes or by substrates of the main transporter proteins.</p><p>Co-administration of fingolimod with ciclosporin did not elicit any change in the ciclosporin or fingolimod exposure. Therefore, fingolimod is not expected to alter the pharmacokinetics of medicinal products that are CYP3A4 substrates.</p><p>Co-administration of fingolimod with oral contraceptives (ethinylestradiol and levonorgestrel) did not elicit any change in oral contraceptive exposure. No interaction studies have been performed with oral contraceptives containing other progestagens, however an effect of fingolimod on their exposure is not expected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential / Contraception in females&nbsp;</u></p><p>Before initiation of treatment in women of childbearing potential, a negative pregnancy test result needs to be available and counselling should be provided regarding the potential for serious risk to the foetus and the need for effective contraception during treatment with Fingolimod Tablets. Since it takes approximately two months to eliminate fingolimod from the body on stopping treatment (see section 4.4), the potential risk to the foetus may persist and contraception should be continued during that period.</p><p><u>Pregnancy&nbsp;</u></p><p>While on treatment, women should not become pregnant and active contraception is recommended. If a woman becomes pregnant while taking Fingolimod Tablets, discontinuation of Fingolimod Tablets is recommended.</p><p>Animal studies have shown reproductive toxicity including foetal loss and organ defects, notably persistent truncus arteriosus and ventricular septal defect (see section 5.3). Furthermore, the receptor affected by fingolimod (sphingosine 1-phosphate receptor) is known to be involved in vascular formation during embryogenesis. There are very limited data from the use of fingolimod in pregnant women.</p><p>There are no data on the effects of fingolimod on labour and delivery.</p><p><u>Breast-feeding&nbsp;</u></p><p>Fingolimod is excreted in milk of treated animals during lactation (see section 5.3). Due to the potential for serious adverse reactions to fingolimod in nursing infants, women receiving Fingolimod Tablets should not breastfeed.</p><p><u>Fertility&nbsp;</u></p><p>Data from preclinical studies do not suggest that fingolimod would be associated with an increased risk of reduced fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fingolimod Tablets has no or negligible influence on the ability to drive and use machines.</p><p>However, dizziness or drowsiness may occasionally occur when initiating therapy with Fingolimod Tablets. On initiation of Fingolimod Tablets treatment it is recommended that patients be observed for a period of 6 hours (see section 4.4, Bradyarrhythmia).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile&nbsp;</p><p>Adverse reactions reported with Fingolimod Tablets 0.5 mg in Studies D2301 (FREEDOMS) and D2309 (FREEDOMS II) are shown below. Adverse reactions derived from post-marketing experience with Fingolimod Tablets via spontaneous case reports or literature cases are also reported. Frequencies were defined using the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).</p><p>Tabulated list of adverse reactions&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections and infestations</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Influenza</p><p>Sinusitis</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Herpes viral infections</p><p>Bronchitis</p><p>Tinea versicolor</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Pneumonia</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Progressive multifocal leukoencephalopathy (PML)**</p><p>Cryptococcal infections**</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Basal cell carcinoma</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Malignant melanoma****</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Lymphoma***</p><p>Squamous cell carcinoma****</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Kaposi&#39;s sarcoma****</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Merkel cell carcinoma***</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Lymphopenia</p><p>Leucopenia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Peripheral oedema***</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions, including rash, urticaria and angioedema upon treatment initiation***</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Depression</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Depressed mood</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Dizziness</p><p>Migraine</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Seizure</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Posterior reversible encephalopathy syndrome (PRES)*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Vision blurred</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Macular oedema</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Bradycardia</p><p>Atrioventricular block</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>T-wave inversion***</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Hypertension</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Cough</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Dyspnoea</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Nausea***</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Eczema</p><p>Alopecia</p><p>Pruritus</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Back pain</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Myalgia</p><p>Arthralgia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Asthenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Investigations</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Hepatic enzyme increased (increased ALT, Gamma glutamyltransferase,</p><p>Aspartate transaminase)</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Blood triglycerides increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Neutrophil count decreased</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>* Not reported in Studies FREEDOMS, FREEDOMS II and TRANSFORMS. The frequency category was based on an estimated exposure of approximately 10,000 patients to fingolimod in all clinical trials. ** PML and cryptococcal infections (including cases of cryptococcal meningitis) have been reported in the post-marketing setting (see section 4.4).</p><p>*** Adverse drug reactions from spontaneous reports and literature</p><p>****<sup> </sup>The frequency category and risk assessment were based on an estimated exposure of more than 24,000 patients to fingolimod 0.5 mg in all clinical trials.</p></td></tr></tbody></table><p>Description of selected adverse reactions&nbsp;</p><p>Infections &nbsp;</p><p>In multiple sclerosis clinical studies the overall rate of infections (65.1%) at the 0.5 mg dose was similar to placebo. However, lower respiratory tract infections, primarily bronchitis and to a lesser extent herpes infection and pneumonia were more common in Fingolimod Tablets-treated patients.</p><p>Some cases of disseminated herpes infection, including fatal cases, have been reported even at the 0.5 mg dose.</p><p>In the post-marketing setting, cases of infections with opportunistic pathogens, such as viral (e.g. varicella zoster virus [VZV], John Cunningham virus [JCV] causing Progressive Multifocal Leukoencephalopathy, herpes simplex virus [HSV]), fungal (e.g. cryptococci including cryptococcal meningitis) or bacterial (e.g. atypical mycobacterium), have been reported, some of which have been fatal (see section 4.4).</p><p>Human papilloma virus (HPV) infection, including papilloma, dysplasia, warts and HPV-related cancer, has been reported under treatment with fingolimod in the post-marketing setting. Due to the immunosuppressive properties of fingolimod, vaccination against HPV should be considered prior to treatment initiation with fingolimod taking into account vaccination recommendations.</p><p>Cancer screening, including Pap test, is recommended as per standard of care.</p><p>Macular oedema &nbsp;</p><p>In multiple sclerosis clinical studies macular oedema occurred in 0.5% of patients treated with the recommended dose of 0.5 mg and 1.1% of patients treated with the higher dose of 1.25 mg. The majority of cases occurred within the first 3-4 months of therapy. Some patients presented with blurred vision or decreased visual acuity, but others were asymptomatic and diagnosed on routine ophthalmological examination. The macular oedema generally improved or resolved spontaneously after discontinuation of Fingolimod Tablets. The risk of recurrence after rechallenge has not been evaluated.</p><p>Macular oedema incidence is increased in multiple sclerosis patients with a history of uveitis (17% with a history of uveitis vs. 0.6% without a history of uveitis). Fingolimod Tablets has not been studied in multiple sclerosis patients with diabetes mellitus, a disease which is associated with an increased risk for macular oedema (see section 4.4). In renal transplant clinical studies in which patients with diabetes mellitus were included, therapy with fingolimod 2.5 mg and 5 mg resulted in a 2-fold increase in the incidence of macular oedema.</p><p>Bradyarrhythmia &nbsp;</p><p>Initiation of Fingolimod Tablets treatment results in a transient decrease in heart rate and may also be associated with atrioventricular conduction delays. In multiple sclerosis clinical studies the maximal decline in heart rate was seen within 6 hours after treatment initiation, with declines in mean heart rate of 12-13 beats per minute for Fingolimod Tablets 0.5 mg. Heart rate below 40 beats per minute in adults, and below 50 beats per minute in paediatric patients, was rarely observed in patients on Fingolimod Tablets 0.5 mg. The average heart rate returned towards baseline within 1 month of chronic treatment. Bradycardia was generally asymptomatic but some patients experienced mild to moderate symptoms, including hypotension, dizziness, fatigue and/or palpitations, which resolved within the first 24 hours after treatment initiation (see also sections 4.4 and 5.1).</p><p>In multiple sclerosis clinical studies first-degree atrioventricular block (prolonged PR interval on ECG) was detected after treatment initiation in adult and paediatric patients. In adult clinical trials it occurred in 4.7% of patients on fingolimod 0.5 mg, in 2.8% of patients on intramuscular interferon beta-1a, and in 1.6% of patients on placebo. Second-degree atrioventricular block was detected in less than 0.2% adult patients on Fingolimod Tablets 0.5 mg. In the post-marketing setting, isolated reports of transient, spontaneously resolving complete AV block have been observed during the six hour monitoring period following the first dose of Fingolimod Tablets. The patients recovered spontaneously. The conduction abnormalities observed both in clinical trials and post-marketing were typically transient, asymptomatic and resolved within the first 24 hours after treatment initiation. Although most patients did not require medical intervention, one patient on Fingolimod Tablets 0.5 mg received isoprenaline for asymptomatic second-degree Mobitz I atrioventricular block.</p><p>In the post-marketing setting, isolated delayed onset events, including transient asystole and unexplained death, have occurred within 24 hours of the first dose. These cases have been confounded by concomitant medicinal products and/or pre-existing disease. The relationship of such events to Fingolimod Tablets is uncertain.</p><p>Blood pressure &nbsp;</p><p>In multiple sclerosis clinical studies Fingolimod Tablets 0.5 mg was associated with an average increase of approximately 3 mmHg in systolic pressure and approximately 1 mmHg in diastolic pressure, manifesting approximately 1 month after treatment initiation. This increase persisted with continued treatment. Hypertension was reported in 6.5% of patients on fingolimod 0.5 mg and in 3.3% of patients on placebo. In the post-marketing setting, cases of hypertension have been reported within the first month of treatment initiation and on the first day of treatment that may require treatment with antihypertensive agents or discontinuation of Fingolimod Tablets (see also section 4.4, Blood pressure effects).</p><p>Liver function &nbsp;</p><p>Increased hepatic enzymes have been reported in adult and paediatric multiple sclerosis patients treated with Fingolimod Tablets. In clinical studies 8.0% and 1.8% of adult patients treated with</p><p>Fingolimod Tablets 0.5 mg experienced an asymptomatic elevation in serum levels of ALT of &ge;3x ULN (upper limit of normal) and &ge;5x ULN, respectively. Recurrence of liver transaminase elevations has occurred upon re-challenge in some patients, supporting a relationship to the medicinal product. In clinical studies, transaminase elevations occurred at any time during treatment although the majority occurred within the first 12 months. ALT levels returned to normal within approximately 2 months after discontinuation of Fingolimod Tablets. In a small number of patients (N=10 on 1.25 mg, N=2 on 0.5 mg) who experienced ALT elevations &ge;5x ULN and who continued on Fingolimod Tablets therapy, the ALT levels returned to normal within approximately 5 months (see also section 4.4, Liver function).</p><p>Nervous system disorders &nbsp;</p><p>In clinical studies, rare events involving the nervous system occurred in patients treated with fingolimod at higher doses (1.25 or 5.0 mg) including ischemic and haemorrhagic strokes and neurological atypical disorders, such as acute disseminated encephalomyelitis (ADEM)-like events.</p><p>Cases of seizures, including status epilepticus, have been reported with the use of Fingolimod Tablets in clinical studies and in the post-marketing setting.</p><p>Vascular disorders &nbsp;</p><p>Rare cases of peripheral arterial occlusive disease occurred in patients treated with fingolimod at higher doses (1.25 mg).</p><p>Respiratory system &nbsp;</p><p>Minor dose-dependent reductions in values for forced expiratory volume (FEV<sub>1</sub>) and diffusion capacity for carbon monoxide (DLCO) were observed with Fingolimod Tablets treatment starting at month 1 and remaining stable thereafter. At month 24, the reduction from baseline values in percentage of predicted FEV<sub>1</sub> was 2.7% for fingolimod 0.5 mg and 1.2% for placebo, a difference that resolved after treatment discontinuation. For DLCO the reductions at month 24 were 3.3% for fingolimod 0.5 mg and 2.7% for placebo.</p><p>Lymphomas &nbsp;</p><p>There have been cases of lymphoma of different varieties, in both clinical studies and the postmarketing setting, including a fatal case of Epstein-Barr virus (EBV) positive B-cell lymphoma. The incidence of lymphoma (B-cell and T-cell) cases was higher in clinical trials than expected in the general population. Some T-cell lymphoma cases were also reported in the post-marketing setting, including cases of cutaneous T-cell lymphoma (mycosis fungoides).</p><p>Haemophagocytic syndrome &nbsp;</p><p>Very rare cases of haemophagocytic syndrome (HPS) with fatal outcome have been reported in patients treated with fingolimod in the context of an infection. HPS is a rare condition that has been described in association with infections, immunosuppression and a variety of autoimmune diseases.</p><p>Paediatric population&nbsp;</p><p>In the controlled paediatric trial D2311 (see section 5.1), the safety profile in paediatric patients (10 to below 18 years of age) receiving fingolimod 0.25 mg or 0.5 mg daily was overall similar to that seen in adult patients. There were, nevertheless, more neurological and psychiatric disorders observed in the study. Caution is needed in this subgroup due to very limited knowledge available from the clinical study.</p><p>In the paediatric study, cases of seizures were reported in 5.6% of fingolimod-treated patients and 0.9% of interferon beta-1a-treated patients.</p><p>Depression and anxiety are known to occur with increased frequency in the multiple sclerosis population. Depression and anxiety have also been reported in paediatric patients treated with fingolimod.</p><p>Mild isolated bilirubin increases have been noted in paediatric patients on fingolimod</p><p><strong><u>Reporting of suspected adverse Reactions</u></strong></p><p>&nbsp;If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects&nbsp;&nbsp;&nbsp; not listed in this leaflet. You can also report side effects directly (see details below). By reporting side affects; you can help provide more information on the safety of this medicine.</p><p><strong><em>&bull; </em>Saudi Arabia<em>:</em></strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:512px"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p><strong><em>o Other GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single doses up to 80 times the recommended dose (0.5 mg) were well tolerated in healthy adult volunteers. At 40 mg, 5 of 6 subjects reported mild chest tightness or discomfort which was clinically consistent with small airway reactivity.</p><p>Fingolimod can induce bradycardia upon treatment initiation. The decline in heart rate usually starts within one hour of the first dose, and is steepest within 6 hours. The negative chronotropic effect of Fingolimod Tablets persists beyond 6 hours and progressively attenuates over subsequent days of treatment (see section 4.4 for details). There have been reports of slow atrioventricular conduction, with isolated reports of transient, spontaneously resolving complete AV block (see sections 4.4 and 4.8).</p><p>If the overdose constitutes first exposure to Fingolimod Tablets, it is important to monitor patients with a continuous (real time) ECG and hourly measurement of heart rate and blood pressure, at least during the first 6 hours (see section 4.4).</p><p>Additionally, if after 6 hours the heart rate is &lt;45 bpm in adults, &lt;55 bpm in paediatric patients aged 12 years and above, or &lt;60 bpm in paediatric patients aged 10 years to below 12 years, or if the ECG at 6 hours after the first dose shows second degree or higher AV block, or if it shows a</p><p>QTc interval &ge;500 msec, monitoring should be extended at least for overnight and until the findings have resolved. The occurrence at any time of third degree AV block should also lead to extended monitoring including overnight monitoring.</p><p>Neither dialysis nor plasma exchange results in removal of fingolimod from the body</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immunosuppressant&rsquo;s, selective immunosuppressant&rsquo;s, ATC code: L04AA27</p><p>Mechanism of action&nbsp;</p><p>Fingolimod is a sphingosine 1-phosphate receptor modulator. Fingolimod is metabolised by sphingosine kinase to the active metabolite fingolimod phosphate. Fingolimod phosphate binds at low nanomolar concentrations to sphingosine 1-phosphate (S1P) receptor 1 located on lymphocytes, and readily crosses the blood-brain barrier to bind to S1P receptor 1 located on neural cells in the central nervous system (CNS). By acting as a functional antagonist of S1P receptors on lymphocytes, fingolimod phosphate blocks the capacity of lymphocytes to egress from lymph nodes, causing a redistribution, rather than depletion, of lymphocytes. Animal studies have shown that this redistribution reduces the infiltration of pathogenic lymphocytes, including pro-inflammatory Th17 cells, into the CNS, where they would be involved in nerve inflammation and nervous tissue damage. Animal studies and <em>in vitro</em> experiments indicate that fingolimod may also act via interaction with S1P receptors on neural cells.</p><p>Pharmacodynamic effects&nbsp;</p><p>Within 4-6 hours after the first dose of fingolimod 0.5 mg, the lymphocyte count decreases to approximately 75% of baseline in peripheral blood. With continued daily dosing, the lymphocyte count continues to decrease over a two-week period, reaching a minimal count of approximately 500 cells/microlitre or approximately 30% of baseline. Eighteen percent of patients reached a minimal count below 200 cells/microlitre on at least one occasion. Low lymphocyte counts are maintained with chronic daily dosing. The majority of T and B lymphocytes regularly traffic through lymphoid organs and these are the cells mainly affected by fingolimod. Approximately 15-20% of T lymphocytes have an effector memory phenotype, cells that are important for peripheral immune surveillance. Since this lymphocyte subset typically does not traffic to lymphoid organs it is not affected by fingolimod. Peripheral lymphocyte count increases are evident within days of stopping fingolimod treatment and typically normal counts are reached within one to two months. Chronic fingolimod dosing leads to a mild decrease in the neutrophil count to approximately 80% of baseline. Monocytes are unaffected by fingolimod.</p><p>Fingolimod causes a transient reduction in heart rate and decrease in atrioventricular conduction at treatment initiation (see sections 4.4 and 4.8). The maximal decline in heart rate is seen within 6 hours post dose, with 70% of the negative chronotropic effect achieved on the first day. With continued administration heart rate returns to baseline within one month. The decrease in heart rate induced by fingolimod can be reversed by parenteral doses of atropine or isoprenaline. Inhaled salmeterol has also been shown to have a modest positive chronotropic effect. With initiation of fingolimod treatment there is an increase in atrial premature contractions, but there is no increased rate of atrial fibrillation/flutter or ventricular arrhythmias or ectopy. Fingolimod treatment is not associated with a decrease in cardiac output. Autonomic responses of the heart, including diurnal variation of heart rate and response to exercise are not affected by fingolimod treatment.</p><p>S1P4 could partially contribute to the effect but was not the main receptor responsible for the lymphoid depletion. The mechanism of action of bradycardia and vasoconstriction were also studied <em>in vitro</em> in guinea pigs and isolated rabbit aorta and coronary artery. It was concluded that bradycardia could be mediated primarily by activation of inward-rectifying potassium channel or G-protein activated inwardly rectifying K<sup>+</sup> channel (IKACh/GIRK) and that vasoconstriction seems to be mediated by a Rho kinase and calcium dependent mechanism.</p><p>Fingolimod treatment with single or multiple doses of 0.5 and 1.25 mg for two weeks is not associated with a detectable increase in airway resistance as measured by FEV<sub>1</sub> and forced expiratory flow rate (FEF) 25-75. However, single fingolimod doses &ge;5 mg (10-fold the recommended dose) are associated with a dose-dependent increase in airway resistance. Fingolimod treatment with multiple doses of 0.5, 1.25, or 5 mg is not associated with impaired oxygenation or oxygen desaturation with exercise or an increase in airway responsiveness to methacholine. Subjects on fingolimod treatment have a normal bronchodilator response to inhaled beta-agonists.</p><p>Clinical efficacy and safety&nbsp;</p><p>The efficacy of Fingolimod Tablets has been demonstrated in two studies which evaluated oncedaily doses of fingolimod 0.5 mg and 1.25 mg in adult patients with relapsing-remitting multiple sclerosis (RRMS). Both studies included adult patients who had experienced &ge;2 relapses in the prior 2 years or &ge;1 relapse during the prior year. Expanded Disability Status Score (EDSS) was between 0 and 5.5. A third study targeting the same adult patient population was completed after registration of Fingolimod Tablets.</p><p>Study D2301 (FREEDOMS) was a 2-year randomised, double-blind, placebo-controlled Phase III study of 1,272 patients (n=425 on 0.5 mg, 429 on 1.25 mg, 418 on placebo). Median values for baseline characteristics were: age 37 years, disease duration 6.7 years, and EDSS score 2.0. Outcome results are shown in Table 1. There were no significant differences between the 0.5 mg and the 1.25 mg doses as regards either endpoint.</p><p>Table 1 Study D2301 (FREEDOMS): main results&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Fingolimod</strong>&nbsp;</p><p><strong>0.5 mg</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Placebo</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Clinical endpoints</strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Annualised relapse rate (primary endpoint)</p></td><td style="vertical-align:top"><p>0.18**</p></td><td style="vertical-align:top"><p>0.40</p></td></tr><tr><td style="vertical-align:top"><p>Percentage of patients remaining relapse-free at 24 months</p></td><td style="vertical-align:top"><p>70%**</p></td><td style="vertical-align:top"><p>46%</p></td></tr><tr><td style="vertical-align:top"><p>Proportion &nbsp;&nbsp;&nbsp;&nbsp; with &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3-month &nbsp;&nbsp;&nbsp;&nbsp; Confirmed &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disability</p><p>Progression&dagger;</p></td><td style="vertical-align:top"><p>17%</p></td><td style="vertical-align:top"><p>24%</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95% CI)</p></td><td style="vertical-align:top"><p>0.70 (0.52, 0.96)*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>MRI endpoints</strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median (mean) number of new or enlarging T2 lesions over 24 months</p></td><td style="vertical-align:top"><p>0.0 (2.5)**</p></td><td style="vertical-align:top"><p>5.0 (9.8)</p></td></tr><tr><td style="vertical-align:top"><p>Median (mean) number of Gd-enhancing lesions at month</p><p>24</p></td><td style="vertical-align:top"><p>0.0 (0.2)**</p></td><td style="vertical-align:top"><p>0.0 (1.1)</p></td></tr><tr><td style="vertical-align:top"><p>Median (mean) % change in brain volume over 24 months</p></td><td style="vertical-align:top"><p>-0.7 (-0.8)**</p></td><td style="vertical-align:top"><p>-1.0 (-1.3)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>&dagger; Disability progression defined as 1-point increase in EDSS confirmed 3 months later</p><p>** p&lt;0.001, *p&lt;0.05 compared to placebo</p><p>All analyses of clinical endpoints were intent-to-treat. MRI analyses used evaluable dataset.</p></td></tr></tbody></table><p>Patients who completed the 24-month core FREEDOMS study could enter a dose-blinded extension study (D2301E1) and receive fingolimod. In total, 920 patients entered (n=331 continued on 0.5 mg, 289 continued on 1.25 mg, 155 switched from placebo to 0.5 mg and 145 switched from placebo to 1.25 mg). After 12 months (month 36), 856 patients (93%) were still enrolled. Between months 24 and 36, the annualised relapse rate (ARR) for patients on fingolimod 0.5 mg in the core study who remained on 0.5 mg was 0.17 (0.21 in the core study). The ARR for patients who switched from placebo to fingolimod 0.5 mg was 0.22 (0.42 in the core study).</p><p>Comparable results were shown in a replicate 2-year randomised, double-blind, placebocontrolled Phase III study on fingolimod in 1,083 patients (n=358 on 0.5 mg, 370 on 1.25 mg, 355 on placebo) with RRMS (D2309; FREEDOMS 2). Median values for baseline characteristics were: age 41 years, disease duration 8.9 years, EDSS score 2.5.</p><p>Table 2 Study D2309 (FREEDOMS 2): main results&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Fingolimod</strong>&nbsp;</p><p><strong>0.5 mg</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Placebo</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Clinical endpoints</strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Annualised relapse rate (primary endpoint)</p></td><td style="vertical-align:top"><p>0.21**</p></td><td style="vertical-align:top"><p>0.40</p></td></tr><tr><td style="vertical-align:top"><p>Percentage of patients remaining relapse-free at 24 months</p></td><td style="vertical-align:top"><p>71.5%**</p></td><td style="vertical-align:top"><p>52.7%</p></td></tr><tr><td style="vertical-align:top"><p>Proportion &nbsp;&nbsp;&nbsp;&nbsp; with &nbsp;&nbsp;&nbsp;&nbsp; 3-month &nbsp;&nbsp;&nbsp; Confirmed &nbsp;&nbsp;&nbsp;&nbsp; Disability</p><p>Progression&dagger;</p></td><td style="vertical-align:top"><p>25%</p></td><td style="vertical-align:top"><p>29%</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95% CI)</p></td><td style="vertical-align:top"><p>0.83 (0.61, 1.12)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>MRI endpoints</strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median (mean) number of new or enlarging T2 lesions over 24 months</p></td><td style="vertical-align:top"><p>0.0 (2.3)**</p></td><td style="vertical-align:top"><p>4.0 (8.9)</p></td></tr><tr><td style="vertical-align:top"><p>Median (mean) number of Gd-enhancing lesions at month 24</p></td><td style="vertical-align:top"><p>0.0 (0.4)**</p></td><td style="vertical-align:top"><p>0.0 (1.2)</p></td></tr><tr><td style="vertical-align:top"><p>Median (mean) % change in brain volume over 24 months</p></td><td style="vertical-align:top"><p>-0.71 (-0.86)**</p></td><td style="vertical-align:top"><p>-1.02 (-1.28)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>&dagger; Disability progression defined as 1-point increase in EDSS confirmed 3 months later</p><p>** p&lt;0.001 compared to placebo</p><p>All analyses of clinical endpoints were intent-to-treat. MRI analyses used evaluable dataset.</p></td></tr></tbody></table><p>Study D2302 (TRANSFORMS) was a 1-year randomised, double-blind, double-dummy, active</p><p>(interferon beta-1a)-controlled Phase III study of 1,280 patients (n=429 on 0.5 mg, 420 on 1.25 mg, 431 on interferon beta-1a, 30 &micro;g by intramuscular injection once weekly). Median values for baseline characteristics were: age 36 years, disease duration 5.9 years, and EDSS score 2.0. Outcome results are shown in Table 3. There were no significant differences between the 0.5 mg and the 1.25 mg doses as regards study endpoints.</p><p>Table 3 Study D2302 (TRANSFORMS): main results&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Fingolimod</strong>&nbsp;</p><p><strong>0.5 mg</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Interferon </strong></p><p><strong>30 &mu;g</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>beta-1a, </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Clinical endpoints</strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Annualised relapse rate (primary endpoint)</p></td><td style="vertical-align:top"><p>0.16**</p></td><td style="vertical-align:top"><p>0.33</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Percentage of patients remaining relapse-free at 12 months</p></td><td style="vertical-align:top"><p>83%**</p></td><td style="vertical-align:top"><p>71%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Proportion &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3-month &nbsp;&nbsp;&nbsp;&nbsp; Confirmed &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disability</p><p>Progression&dagger;</p></td><td style="vertical-align:top"><p>&nbsp;6%</p></td><td style="vertical-align:top"><p>8%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95% CI)</p></td><td style="vertical-align:top"><p>0.71 (0.42, 1.21)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>MRI endpoints</strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median (mean) number of new or enlarging T2 lesions over 12 months</p></td><td style="vertical-align:top"><p>0.0 (1.7)*</p></td><td style="vertical-align:top"><p>1.0 (2.6)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median (mean) number of Gd-enhancing lesions at 12 months</p></td><td style="vertical-align:top"><p>0.0 (0.2)**</p></td><td style="vertical-align:top"><p>0.0 (0.5)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median (mean) % change in brain volume over 12 months</p></td><td style="vertical-align:top"><p>-0.2 (-0.3)**</p></td><td style="vertical-align:top"><p>-0.4 (-0.5)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>&dagger; Disability progression defined as 1-point increase in EDSS confirmed 3 months later.</p><p>* p&lt;0.01,** p&lt;0.001, compared to interferon beta-1a</p><p>All analyses of clinical endpoints were intent-to-treat. MRI analyses used evaluable dataset.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>Patients who completed the 12-month core TRANSFORMS study could enter a dose-blinded extension (D2302E1) and receive fingolimod. In total, 1,030 patients entered, however, 3 of these patients did not receive treatment (n=356 continued on 0.5 mg, 330 continued on 1.25 mg,</p><p>167 switched from interferon beta-1a to 0.5 mg and 174 from interferon beta-1a to 1.25 mg).</p><p>After 12 months (month 24), 882 patients (86%) were still enrolled. Between months 12 and 24, the ARR for patients on fingolimod 0.5 mg in the core study who remained on 0.5 mg was 0.20 (0.19 in the core study). The ARR for patients who switched from interferon beta-1a to fingolimod 0.5 mg was 0.33 (0.48 in the core study).</p><p>Pooled results of Studies D2301 and D2302 showed a consistent and statistically significant reduction in annualised relapse rate compared to comparator in subgroups defined by gender, age, prior multiple sclerosis therapy, disease activity or disability levels at baseline.</p><p>Further analyses of clinical trial data demonstrate consistent treatment effects in highly active subgroups of relapsing remitting multiple sclerosis patients.</p><p>Paediatric population&nbsp;</p><p>The efficacy and safety of once-daily doses of fingolimod 0.25 mg or 0.5 mg (dose selected based on body weight and exposure measurements) have been established in paediatric patients aged 10 to &lt;18 years with relapsing-remitting multiple sclerosis.</p><p>Study D2311 (PARADIGMS) was a double-blind, double-dummy, active-controlled study with flexible duration up to 24 months, with 215 patients 10 to &lt;18 years old (n=107 on fingolimod, 108 on interferon beta-1a 30 &micro;g by intramuscular injection once weekly).</p><p>Median values for baseline characteristics were: age 16 years, median disease duration 1.5 years and EDSS score 1.5. The majority of patients were Tanner stage 2 or higher (94.4%) and were &gt;40 kg (95.3%). Overall, 180 (84%) of patients completed the core phase on study drug (n=99 [92.5%] on fingolimod, 81 [75%] on interferon beta-1a). Outcome results are shown in Table 4.</p><p>Table 4 Study D2311 (PARADIGMS): main results&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Fingolimod</strong>&nbsp;</p><p><strong>0.25 mg or 0.5 mg</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Interferon beta-1a</strong>&nbsp;</p><p><strong>30 &micro;g</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Clinical endpoints</strong>&nbsp;</p></td><td style="vertical-align:top"><p>N=107</p></td><td style="vertical-align:top"><p>N=107<sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p>Annualised relapse rate (primary endpoint)</p></td><td style="vertical-align:top"><p>0.122**</p></td><td style="vertical-align:top"><p>0.675</p></td></tr><tr><td style="vertical-align:top"><p>Percentage of patients remaining relapse-free at 24 months</p></td><td style="vertical-align:top"><p>85.7**</p></td><td style="vertical-align:top"><p>38.8</p></td></tr><tr><td style="vertical-align:top"><p><strong>MRI endpoints</strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Annualised rate of the number of new or newly enlarging</p><p>T2 lesions&nbsp;</p></td><td style="vertical-align:top"><p>n=106</p></td><td style="vertical-align:top"><p>n=102</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted mean</p></td><td style="vertical-align:top"><p>4.393**</p></td><td style="vertical-align:top"><p>9.269</p></td></tr><tr><td style="vertical-align:top"><p>Number of Gd-enhancing T1 lesions per scan up to month</p><p>24</p></td><td style="vertical-align:top"><p>n=105</p></td><td style="vertical-align:top"><p>n=95</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted mean</p></td><td style="vertical-align:top"><p>0.436**</p></td><td style="vertical-align:top"><p>1.282</p></td></tr><tr><td style="vertical-align:top"><p>Annualised rate of brain atrophy from baseline up to month 24</p></td><td style="vertical-align:top"><p>n=96</p></td><td style="vertical-align:top"><p>n=89</p></td></tr><tr><td style="vertical-align:top"><p>Least Square Mean</p></td><td style="vertical-align:top"><p>-0.48*</p></td><td style="vertical-align:top"><p>-0.80</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p># One patient randomised to receive interferon beta-1a by intramuscular injection was unable to swallow the double-dummy medication and discontinued from study. The patient was excluded from the full analysis and safety set.</p><p>* p&lt;0.05, ** p&lt;0.001, compared to interferon beta-1a.</p><p>All analyses of clinical endpoints were on the full analysis set.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacokinetic data were obtained in healthy adult volunteers, in renal transplant adult patients and in multiple sclerosis adult patients.</p><p>The pharmacologically active metabolite responsible for efficacy is fingolimod phosphate.</p><p><u>Absorption&nbsp;</u></p><p>Fingolimod absorption is slow (t<sub>max</sub> of 12-16 hours) and extensive (&ge;85%). The apparent absolute oral bioavailability is 93% (95% confidence interval: 79-111%). Steady-state-blood concentrations are reached within 1 to 2 months following once-daily administration and steadystate levels are approximately 10-fold greater than with the initial dose.</p><p>Food intake does not alter C<sub>max</sub> or exposure (AUC) of fingolimod. Fingolimod phosphate C<sub>max</sub> was slightly decreased by 34% but AUC was unchanged. Therefore, Fingolimod Tablets may be taken without regard to meals (see section 4.2).</p><p><u>Distribution&nbsp;</u></p><p>Fingolimod highly distributes in red blood cells, with the fraction in blood cells of 86%. Fingolimod phosphate has a smaller uptake in blood cells of &lt;17%. Fingolimod and fingolimod phosphate are highly protein bound (&gt;99%).</p><p>Fingolimod is extensively distributed to body tissues with a volume of distribution of about 1,200&plusmn;260 litres. A study in four healthy subjects who received a single intravenous dose of a radioiodolabelled analogue of fingolimod demonstrated that fingolimod penetrates into the brain. In a study in 13 male multiple sclerosis patients who received Fingolimod Tablets 0.5 mg/day, the mean amount of fingolimod (and fingolimod phosphate) in seminal ejaculate, at steady-state, was approximately 10,000 times lower than the oral dose administered (0.5 mg).</p><p><u>Biotransformation&nbsp;</u></p><p>Fingolimod is transformed in humans by reversible stereoselective phosphorylation to the pharmacologically active (S)-enantiomer of fingolimod phosphate. Fingolimod is eliminated by oxidative biotransformation catalysed mainly via CYP4F2 and possibly other isoenzymes and subsequent fatty acid-like degradation to inactive metabolites. Formation of pharmacologically inactive non-polar ceramide analogues of fingolimod was also observed. The main enzyme involved in the metabolism of fingolimod is partially identified and may be either CYP4F2 or CYP3A4.</p><p>Following single oral administration of [<sup>14</sup>C] fingolimod, the major fingolimod-related components in blood, as judged from their contribution to the AUC up to 34 days post dose of total radiolabelled components, are fingolimod itself (23%), fingolimod phosphate (10%), and inactive metabolites (M3 carboxylic acid metabolite (8%), M29 ceramide metabolite (9%) and M30 ceramide metabolite (7%)).</p><p><u>Elimination&nbsp;</u></p><p>Fingolimod blood clearance is 6.3&plusmn;2.3 l/h, and the average apparent terminal half-life (t<sub>1/2</sub>) is 6-9 days. Blood levels of fingolimod and fingolimod phosphate decline in parallel in the terminal phase, leading to similar half-lives for both.</p><p>After oral administration, about 81% of the dose is slowly excreted in the urine as inactive metabolites. Fingolimod and fingolimod phosphate are not excreted intact in urine but are the major components in the faeces, with amounts representing less than 2.5% of the dose each.</p><p>After 34 days, the recovery of the administered dose is 89%.</p><p><u>Linearity&nbsp;</u></p><p>Fingolimod and fingolimod phosphate concentrations increase in an apparently dose proportional manner after multiple once-daily doses of 0.5 mg or 1.25 mg.</p><p>Characteristics in specific groups of patients&nbsp;</p><p>The pharmacokinetics of fingolimod and fingolimod phosphate do not differ in males and females, in patients of different ethnic origin, or in patients with mild to severe renal impairment.</p><p>In subjects with mild, moderate, or severe hepatic impairment (Child-Pugh class A, B, and C), no change in fingolimod C<sub>max</sub> was observed, but fingolimod AUC was increased respectively by 12%, 44%, and 103%. In patients with severe hepatic impairment (Child-Pugh class C), fingolimod-phosphate C<sub>max</sub> was decreased by 22% and AUC was not substantially changed. The pharmacokinetics of fingolimod-phosphate were not evaluated in patients with mild or moderate hepatic impairment. The apparent elimination half-life of fingolimod is unchanged in subjects with mild hepatic impairment, but is prolonged by about 50% in patients with moderate or severe hepatic impairment.</p><p>Fingolimod should not be used in patients with severe hepatic impairment (Child-Pugh class C) (see section 4.3). Fingolimod should be introduced cautiously in mild and moderate hepatic impaired patients (see section 4.2).</p><p>Clinical experience and pharmacokinetic information in patients aged above 65 years are limited. Fingolimod Tablets should be used with caution in patients aged 65 years and over (see section</p><p>4.2).</p><p><u>Paediatric population&nbsp;</u></p><p>In paediatric patients (10 years of age and above), fingolimod-phosphate concentrations increase in an apparent dose proportional manner between 0.25 mg and 0.5 mg.</p><p>Fingolimod-phosphate concentration at steady state is approximately 25% lower in paediatric patients (10 years of age and above) following daily administration of 0.25 mg or 0.5 mg fingolimod compared to the concentration in adult patients treated with fingolimod 0.5 mg once daily.</p><p>There are no data available for paediatric patients below 10 years old</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The preclinical safety profile of fingolimod was assessed in mice, rats, dogs and monkeys. The major target organs were the lymphoid system (lymphopenia and lymphoid atrophy), lungs (increased weight, smooth muscle hypertrophy at the bronchio-alveolar junction), and heart (negative chronotropic effect, increase in blood pressure, perivascular changes and myocardial degeneration) in several species; blood vessels (vasculopathy) in rats only at doses of 0.15 mg/kg and higher in a 2-year study, representing an approximate 4-fold margin based on the human systemic exposure (AUC) at a daily dose of 0.5 mg.</p><p>No evidence of carcinogenicity was observed in a 2-year bioassay in rats at oral doses of fingolimod up to the maximally tolerated dose of 2.5 mg/kg, representing an approximate 50fold margin based on human systemic exposure (AUC) at the 0.5 mg dose. However, in a 2-year mouse study, an increased incidence of malignant lymphoma was seen at doses of 0.25 mg/kg and higher, representing an approximate 6-fold margin based on the human systemic exposure (AUC) at a daily dose of 0.5 mg.</p><p>Fingolimod was neither mutagenic nor clastogenic in animal studies.</p><p>Fingolimod had no effect on sperm count/motility or on fertility in male and female rats up to the highest dose tested (10 mg/kg), representing an approximate 150-fold margin based on human systemic exposure (AUC) at a daily dose of 0.5 mg.</p><p>Fingolimod was teratogenic in the rat when given at doses of 0.1 mg/kg or higher. Drug exposure in rats at this dose was similar to that in patients at the therapeutic dose (0.5 mg). The most common foetal visceral malformations included persistent truncus arteriosus and ventricular septum defect. The teratogenic potential in rabbits could not be fully assessed, however an increased embryo-foetal mortality was seen at doses of 1.5 mg/kg and higher, and a decrease in viable foetuses as well as foetal growth retardation was seen at 5 mg/kg. Drug exposure in rabbits at these doses was similar to that in patients.</p><p>In rats, F1 generation pup survival was decreased in the early postpartum period at doses that did not cause maternal toxicity. However, F1 body weights, development, behaviour, and fertility were not affected by treatment with fingolimod.</p><p>Fingolimod was excreted in milk of treated animals during lactation at concentrations 2-fold to 3-fold higher than that found in maternal plasma. Fingolimod and its metabolites crossed the placental barrier in pregnant rabbits.</p><p>Juvenile animal studies&nbsp;</p><p>Results from two toxicity studies in juvenile rats showed slight effects on neurobehavioural response, delayed sexual maturation and a decreased immune response to repeated stimulations with keyhole limpet haemocyanin (KLH), which were not considered adverse. Overall, the treatment-related effects of fingolimod in juvenile animals were comparable to those seen in adult rats at similar dose levels, with the exception of changes in bone mineral density and neurobehavioural impairment (reduced auditory startle response) observed at doses of 1.5 mg/kg and higher in juvenile animals and the absence of smooth muscle hypertrophy in the lungs of the juvenile rats.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Sphingolin 0.5mg</strong></p><p>The other ingredients are: Powder cellulose, Titanium dioxide, Magnesium stearate.</p><p>Capsule composition: gelatin, titanium dioxide, iron oxide yellow, purified water no added preservatives</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>3 X 10&#39;s Clear PVC / PVdC-Alu Blister Pack&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Hetero Lab  
Aljameah Street, Malaz quarter, Riyadh 11441 
Saudi Arabia 
Tel: +966 11 477 2215
Manufacture: 
Hetero Lab Unit V, Hyderabad, India  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NA
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>